ginsenoside rh2 has been researched along with ginsenosides in 278 studies
| Studies (ginsenoside rh2) | Trials (ginsenoside rh2) | Recent Studies (post-2010) (ginsenoside rh2) | Studies (ginsenosides) | Trials (ginsenosides) | Recent Studies (post-2010) (ginsenosides) |
|---|---|---|---|---|---|
| 295 | 1 | 200 | 4,821 | 61 | 3,179 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.08) | 18.7374 |
| 1990's | 19 (6.83) | 18.2507 |
| 2000's | 61 (21.94) | 29.6817 |
| 2010's | 138 (49.64) | 24.3611 |
| 2020's | 57 (20.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, H; Yuan, C; Zhao, Y | 1 |
| Maeda, M; Odashima, S; Ota, T | 1 |
| Hirata, J; Kikuchi, Y; Kita, T; Nagata, I; Sasa, H; Tode, T | 1 |
| Abe, H; Fujikawa-Yamamoto, K; Odashima, S; Ota, T | 1 |
| Chen, YJ; Pei, YP; Xie, H; Xu, SX; Yao, XS | 1 |
| Cheng, YJ; Ma, QF; Pei, YP; Su, SX; Xie, H; Yao, XS | 1 |
| Kohno, H; Maeda, M; Odashima, S; Ota, T; Tanino, M | 1 |
| Hirata, J; Imaizumi, E; Kikuchi, Y; Kita, T; Nagata, I; Tode, T | 2 |
| Chung, HT; Kang, HS; Kim, HD; Kim, KW; Lee, CH; Park, YC | 1 |
| Maeda, M; Ninomiya-Tsuji, J; Odashima, S; Ota, T; Tatsuka, M | 1 |
| Chung, E; Kim, SI; Lee, KY; Lee, SK; Lee, YH; Park, JA | 1 |
| Byun, BH; Joe, CO; Kim, SI; Shin, I; Yoon, YS | 1 |
| Kim, KW; Lee, KY; Lee, SK; Oh, YJ; Park, JA | 1 |
| Kashimoto, T; Kudo, K; Tachikawa, E; Takahashi, E | 1 |
| Kim, DS; Kim, SI; Kim, YS | 1 |
| Hirata, J; Ishii, K; Kikuchi, Y; Kita, T; Kudoh, K; Nagata, I; Nakata, H; Shinomiya, N; Tode, T | 1 |
| Kim, KW; Kim, SI; Lee, SK; Park, JA | 1 |
| Han, R; Xia, LJ | 1 |
| Choi, S; Choi, YH; Chung, H; Kim, DK; Kim, K; Kim, ND; Kim, SI; Oh, M | 1 |
| Kim, HE; Lee, SK; Oh, JH; Oh, YJ | 1 |
| Jin, SH; Kim, SI; Kim, YS; Lee, YH; Park, JD | 2 |
| Jin, YH; Lee, SK; Lee, YH; Yoo, KJ | 1 |
| Maeda, M; Ota, T; Tatsuka, M | 1 |
| Fei, XF; Ikejima, T; Li, TJ; Ma, JS; Tashiro, S; Wang, BX | 1 |
| Chen, H; Chen, Y; Duan, X; Guo, L; Zhan, E | 1 |
| Choi, JS; Chun, KH; Ham, YM; Kim, DH; Lee, SK | 1 |
| Choi, JS; Chun, KH; Ham, YM; Joo, SH; Lee, SK | 1 |
| Choi, HJ; Jin, YH; Lee, SK; Park, BD; Yim, H | 1 |
| Choo, MK; Han, MJ; Kim, DH; Kim, EJ; Park, EK | 1 |
| Tu, ZG; Zeng, XL | 4 |
| Bae, EA; Han, MJ; Kim, DH; Kim, EJ | 1 |
| Choo, MK; Kim, DH; Oh, JK; Park, EK; Ryu, JH | 1 |
| Kitts, DD; Popovich, DG | 2 |
| Choi, KJ; Im, DS; Kim, HS; Ko, SR; Lee, EH; Park, JH | 1 |
| Bu, X; Bush, JA; Chen, X; Jia, WW; Li, G; Liu, G; Philips, D; Yan, H | 1 |
| Jin, SH; Kim, YS | 1 |
| Chen, M; Huang, CR; Jiang, XL; Li, H; Lv, H; Roberts, M; Wang, GJ; Wang, R; Xie, HT | 1 |
| Chen, X; Li, K; Li, X; Xu, J; Zhong, D | 1 |
| Jiang, XL; Li, H; Sun, JG; Tucker, I; Wang, GJ; Wang, R; Wang, W; Xie, HT; Xie, YY; Xu, MJ; Zhao, XC | 1 |
| Chang, WM; Chen, JC; Cheng, CC; Hsu, SL; Huang, CY; Yang, SM | 1 |
| Hu, CP; Hu, S; Liang, CH | 1 |
| Bae, EA; Han, MJ; Kim, DH; Lee, HU | 1 |
| Cai, Z; Jiang, ZH; Qian, T; Wong, RN | 1 |
| Chun, KH; Joo, SH; Lee, SK; Oh, JI; Oh, YT | 1 |
| Duan, Y; Law, V; Nicholson, R; Zheng, J | 1 |
| Li, L; Liu, JR; Qi, FY; Zuo, LF | 1 |
| Chen, PF; Cheng, JT; Lai, DM; Liu, IM; Tu, YK | 1 |
| Choo, MK; Chung, KC; Kim, DH; Kim, S; Lee, E; Nam, G; Rhim, H | 1 |
| Eberding, A; Fazli, L; Gleave, M; Goldenberg, L; Guns, ES; Jia, W; Madera, C; Xie, X | 1 |
| Li, G; Liu, K; Wang, Z; Zheng, Q; Zheng, R | 1 |
| Gu, Y; Jia, Y; Sun, J; Wang, G; Wang, W; Xu, M | 1 |
| Bae, EA; Kim, DH; Kim, EJ; Kim, HS; Park, JS; Ryu, JH | 1 |
| Gui, MY; Jin, YR; Li, XW; Zhang, HQ; Zheng, Y | 1 |
| Bae, EA; Han, MJ; Kim, DH; Shin, YW | 1 |
| Choi, JS; Ham, YM; Lee, SK; Lim, JH; Na, HK; Park, BD; Yim, H | 1 |
| Deng, SG; Liu, YM; Ou, RM; Wu, ZF; Xu, SJ; Yang, L; Zeng, X | 1 |
| Gu, Y; Jia, YW; Sun, JG; Wang, GJ; Wang, W; Xie, HT | 1 |
| Cheng, JT; Kao, ST; Lee, WK; Liu, IM | 1 |
| Choi, C; Choi, K; Kim, M; Ryu, J | 1 |
| Gu, J; Xu, J; Zhang, D; Zhang, X; Zhao, Y | 1 |
| Han, SJ; Hyun, JW; Kim, DH; Kim, HS; Kim, SY | 1 |
| Ha, J; Hwang, JT; Kim, HS; Kim, MJ; Kim, MS; Kim, SH; Kwon, DY; Lee, MS; Yang, HJ | 1 |
| Hu, CP; Liang, S; Yang, HZ; Zhou, DB | 1 |
| Han, SJ; Kim, DH; Kim, SW; Lee, YC; Trinh, HT | 1 |
| Hu, C; Kitts, DD; Popovich, DG | 1 |
| Hill, DL; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhao, Y | 1 |
| Duan, Y; Nicholson, RA | 1 |
| Cheng, JT; Kou, DH; Li, JS; Shieh, PC; Tsao, CW; Wen, YJ; Wu, HT | 1 |
| Cheng, JT; Niu, CS; Yeh, CH; Yeh, MF | 1 |
| Lv, XH; Wang, Q; Wu, MQ; Yang, HK; Zhao, LH | 1 |
| Su, JH; Wang, ZL; Xu, JH | 1 |
| Choi, HJ; Kim, DH; Kim, NJ; Kim, TW | 1 |
| Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C | 1 |
| Jin, F; Kondo, R; Liu, J; Shimizu, K; Shiono, J; Yu, H; Zhang, C | 1 |
| Cho, BR; Choo, HJ; Ham, YM; Kim, HM; Kim, YN; Ko, YG; Yi, JS | 1 |
| Gu, Y; Jia, YW; Lv, T; Sai, Y; Sun, JG; Wang, GJ; Wang, W; Xu, MJ; Zheng, YT | 1 |
| Choi, S; Kim, TW; Singh, SV | 1 |
| Han, SJ; Jang, IS; Kim, DH; Ryu, JH; Yang, JH | 1 |
| Hu, CP; Hu, S; Xiong, LJ; Yu, JY; Zhang, YX | 1 |
| Amosova, EN; Atopkina, LN; Kozlovskaia, EP; Krylova, SG; Lopatina, KA; Popov, AM; Razina, TG; Zueva, EP | 1 |
| Jin, F; Kondo, R; Liu, J; Shimizu, K; Yu, H; Zhang, C | 1 |
| Hwang, EH; Jeong, KC; Kim, CW; Kim, YN; Koo, KH; Lee, EJ; Lee, SH; Park, BK; Park, EK; Park, JH; Sung, JY | 1 |
| Ai, H; Gu, Y; Jia, YW; Sun, JG; Wang, GJ; Wu, XL; Zhang, JW; Zheng, YT | 1 |
| Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E | 1 |
| Ai, H; Gu, Y; Hao, G; Li, Y; Peng, Y; Sun, J; Wang, G; Wu, X; Zhang, J; Zhang, X; Zheng, Y; Zhou, F | 1 |
| Jiang, YS; Jin, ZX; Ota, T; Umehara, H | 1 |
| Choi, S; Kim, SJ; Oh, JY | 1 |
| Du, W; He, TC; Li, B; Searle, J; Wang, CZ; Yuan, CS; Zhao, J | 1 |
| Feng, H; Hu, R; Li, M; Wu, GC; Wu, N | 1 |
| Chen, Y; Hao, G; Lu, M; Niu, F; Peng, Y; Sun, J; Sun, Y; Wang, G; Wu, X; Zha, BS; Zhang, J; Zhang, X; Zhou, F | 1 |
| Fang, X; Guo, X; He, K; Jin, YH; Li, Q; Li, Y; Sun, C; Wang, X; Zhan, Z | 1 |
| Gao, S; Hu, M; Jiang, Z; Teng, Y; Wang, J; Wu, B; Yang, Z; Yin, T; You, M | 1 |
| Chung, SH; Huang, B; Jung, MS; Kim, DY; Park, KH; Quan, HY; Yuan, HD | 1 |
| Hou, J; Yu, H; Zhang, C | 1 |
| Chen, HF; Chen, QC; Li, W; Lin, T; Liu, WC; Wei, GQ; Zeng, JZ; Zhang, WY; Zhang, XK; Zheng, YN | 1 |
| Bao, J; Li, C; Liu, Y; Qi, P; Wang, H; Wang, Y | 1 |
| Tan, L; Tang, H; Xiao, X; Xie, Q; Xu, L; Yao, S; Zhang, Y; Zhou, B; Zhu, L | 1 |
| Ahn, JS; He, L; Jang, JH; Kim, BY; Kim, HH; Lee, J; Lee, SG; Lee, SH; Nan, MH; Oh, BC; Soung, NK | 1 |
| Lu, M; Niu, F; Sun, J; Wang, G; Wu, X; Zhang, J; Zhou, F | 1 |
| Bi, WY; Fu, BD; Li, HP; Lv, S; Qin, QQ; Shen, HQ; Song, Z; Wei, Q; Wei, XB; Wu, SC; Yi, PF; Zhang, C | 1 |
| Kang, HS; Kim, JS; Kim, SJ; Park, HM | 1 |
| Hao, G; Lu, M; Sun, H; Wang, G; Wu, X; Zhang, J; Zhou, F | 1 |
| Hou, J; Li, W; Liu, L; Sung, C; Wang, C; Wang, Z; Xue, J; Zhang, D; Zheng, Y | 1 |
| Chen, X; Li, L; Zhong, D; Zhou, J | 1 |
| Cho, SH; Choi, JH; Choi, SY; Chung, KS; Hong, HD; Kim, DH; Lee, KT; Rhee, YK; Shin, JS | 1 |
| An, IS; An, S; Bae, S; Kim, YJ; Kwon, KJ | 1 |
| Bi, WY; Fu, BD; He, CL; Shen, HQ; Wang, DC; Wang, L; Wei, XB; Yi, PF; Zhu, W | 1 |
| Choi, WY; Lim, CJ; Lim, HW | 1 |
| Guo, Q; Guo, XX; Jin, YH; Lee, SK; Li, Y; Wei, XN | 1 |
| Fang, CY; Liang, ZH; Tang, GD; Tang, XP; Zhang, LY | 1 |
| Bae, SH; Bae, SK; Jang, MJ; Kim, JY; Kim, SO; Seo, JH; Yoo, YH; Zheng, YF | 1 |
| Bai, HL; Bi, WY; Dong, HB; Fu, BD; Lv, S; Qin, QQ; Shen, HQ; Song, Z; Wei, Q; Wei, XB; Wu, SC; Yi, PF; Zhang, C; Zhang, LY | 1 |
| Aa, JY; Cao, B; Ge, C; Gu, RR; Li, MJ; Liu, CX; Liu, LS; Ma, T; Mao, Y; Shi, J; Sun, RB; Wang, GJ; Wang, XW; Wu, XL; Xia, WJ; Xiao, WJ; Yu, XY; Zha, WB; Zheng, T; Zhou, J | 1 |
| Hou, J; Lee, M; Liu, L; Sun, M; Sung, C; Xue, J; Zhang, D; Zheng, Y | 1 |
| Bae, KH; Cho, S; Kim, H; Kim, JH; Lee, PY; Park, BC; Park, SG; Shin, H | 1 |
| Dong, HB; Fu, BD; Guo, X; Lv, S; Shen, HQ; Wei, XB; Wu, SC; Xia, F; Yi, PF; Zhang, LY | 1 |
| Fang, JP; Lao, CH; Wang, JC; Xia, T; Xu, LH; Xu, W; Ye, QX | 1 |
| Deng, ZY; Hu, JN; Li, HY; Li, W; Tsao, R; Ye, H; Zhang, B; Zheng, YN; Zhu, XM | 1 |
| Cheng, T; Gao, Y; Guo, W; Li, S; Liu, Y; Ma, W; Zhou, G | 1 |
| Guo, XX; Jiang, D; Jin, FX; Jin, YH; Lee, SK; Li, Y; Lin, YJ; Sun, C | 1 |
| Chen, D; Li, G; Mu, H; Shen, Y; Yu, H | 1 |
| Feng, SH; He, ZY; Li, W; Qiu, J; Wang, M | 1 |
| Guo, C; Wu, Q; Ye, H; Zheng, X; Zhu, Y | 1 |
| Chen, D; Li, D; Li, J; Wei, Q; Xia, J; You, Z; Zhao, L | 1 |
| Bae, SH; Bae, SK; Jang, MJ; Kim, JY; Kim, SO; Oh, E; Park, JB; Yoo, YH; Yoon, KD; Zheng, YF | 1 |
| Chen, HY; Chen, WC; Chen, YH; Hsieh, WT; Lin, YN | 1 |
| Chen, D; Feng, Z; Li, D; Li, J; Luo, L; Shi, Q; Xia, J; You, Z; Zhao, L; Zuo, G | 1 |
| Chen, Q; He, J; Liu, J; Lu, M; Sun, X; Sun, Y; Wang, G; Wang, Y; Zhang, J; Zhang, X; Zhou, F | 1 |
| Choi, WY; Lee, S; Lim, CJ; Oh, SJ | 1 |
| Ersam, T; Fatmawati, S; Jin, F; Shimizu, K; Yu, H; Zhang, C | 1 |
| Chen, Y; Gao, W; Li, D; Qian, G; Qu, X; Sui, D; Wang, B; Wang, Z; Zhao, J | 1 |
| Chen, D; Li, D; Li, J; Liu, Z; Wei, Q; Xia, J; You, Z; Zuo, G | 1 |
| Hong, B; Niu, T; Wu, S; Zhang, Q | 1 |
| Gao, Y; Guo, W; Li, S; Liu, Y | 1 |
| Chen, W; Qiu, Y | 1 |
| Al-Shaiji, TF; Malallah, MA | 1 |
| Chen, Z; Wu, D | 1 |
| Tang, JH; Wen, X; Yao, YF; Zhang, HD; Zhao, JH; Zhao, L | 1 |
| Cheong, JH; Hong, MJ; Kim, H; Kim, HP; Kim, J; Kim, JW; Park, JH; Sung, SH; Yang, H; Yang, MH; Yoo, H | 1 |
| Fan, Y; Liu, Q; Wang, P; Wei, W; Wei, Y; Yan, X; Yang, C; Yue, J; Zhang, L; Zhao, G; Zhou, Z | 1 |
| Guan, N; Guo, W; Huo, X; Luo, J; Zhang, S; Zhang, Z | 1 |
| Cao, L; Chang, C; Chen, M; Jia, C; Li, P; Liu, S; Liu, Z; Qiu, Y; Wu, Y | 1 |
| Ding, Y; Gao, Y; Yi, X; Zhou, J | 1 |
| Gong, J; Kong, D; Zhang, H | 1 |
| Wang, X; Wang, Y | 1 |
| Chen, F; Deng, Z; Hu, J; Xiong, Z; Yang, J; Zhang, B | 1 |
| Chen, DL; Chen, Y; Jiang, R; Li, J; Li, XP; Liu, ZH; Xia, J; Xiong, W; Zuo, GW | 1 |
| Choi, YH; Li, LC; Lin, ZH; Piao, HM; Yan, GH; Zheng, MY | 1 |
| Li, Z; Lou, C; Yang, H; Zhang, H; Zhong, Z; Zhou, Z | 1 |
| Chen, F; Deng, ZY; Hu, JN; Tan, CL; Xiong, ZX; Zhang, B; Zheng, SL | 1 |
| Li, F; Liu, F; Qian, W; Zhang, T; Zhu, C | 1 |
| Chen, Y; Gao, Y; Jin, Y; Li, X; Li, Y; Sun, T; Yang, J | 1 |
| Oh, TW; Park, YK; Vinoth Kumar, R | 1 |
| Liu, H; Yang, Z; Zhang, L; Zhao, T | 1 |
| Bai, LP; Chan, KM; Chan, RW; Dong, H; Guo, J; Guo, Y; Hsiao, WW; Jiang, ZH; Kam, RK; Kong, AN; Law, BY; Leung, EL; Liang, X; Liu, L; Wang, J; Wang, R; Wong, VK; Yen, FG; Yu, Z; Zhang, W; Zhou, H | 1 |
| Chen, X; Ding, Y; Le, J; Li, X; Peng, M; Yang, Y; Yi, Y; Zhang, T | 1 |
| Cai, J; Chen, Q; Fang, J; Huang, W; Song, J; Wang, J; Wang, M; Wang, Y; Xia, T; Yu, Z | 1 |
| Chen, F; Deng, ZY; Hu, JN; Peng, H; Sun, Y; Xiong, ZX; Zhang, B | 1 |
| Chen, DL; Chen, Y; Li, J; Li, KQ; Li, XP; Liu, ZH; Xia, J; Xiong, W | 1 |
| Jin, FX; Liu, JT; Liu, LJ; Lv, Q; Rong, N; Wang, CM; Xu, XL | 1 |
| Huang, J; Li, J; Luo, T; Luo, Z; Peng, K; Su, M; Wang, L; Wen, B; Zhou, L | 1 |
| Guo, CX; Jia, JG; Jin, X; Li, J; Qian, J; Qian, LY; Xie, B; Yu, DJ | 1 |
| Lei, T; Wang, S; Zhang, M | 1 |
| Bin Kang, K; Cho, CH; Chung, JW; Han, S; Jeong, AJ; Kim, BH; Lee, H; Sung, SH; Yang, H; Ye, SK; Yi, EH | 1 |
| Chen, DL; Chen, Y; Guo, P; Li, H; Li, J; Shi, Q; Shi, X; Wang, F; Xiong, W; Zuo, G | 1 |
| Li, S; Liu, X; Qi, X; Sun, Y; Yang, Y; Yu, H; Yue, L; Zhang, C; Zhao, H | 1 |
| Choi, JS; Kim, JH | 1 |
| Chen, Y; Huang, M; Li, T; Liu, C; Liu, M; Liu, Y; Mo, R; Qu, D; Shen, S; Wang, L | 1 |
| Cui, CH; Han, NS; Im, WT; Kim, SC; Park, SK; Siddiqi, MZ | 1 |
| Fang, JP; Liu, Y; Wang, M; Wang, YN; Wu, LM; Xia, T; Yao, JH; Zeng, QH; Zhang, XL; Zhou, CX | 1 |
| Fan, C; Guo, M; Li, P; Ling, Y; Qu, D; Zhou, T; Zhou, X | 1 |
| Ahn, S; Castro-Aceituno, V; Kim, YJ; Singh, H; Singh, P; Yang, DC | 1 |
| Chen, ZC; Cheng, JT; Hsu, CT; Lo, SH; Niu, CS; Niu, HS | 1 |
| Chang, Q; Hu, X; Liao, Y; Liu, C; Liu, X; Pan, R; Yang, F; Yu, SK; Zhou, J | 1 |
| Chen, DL; Chen, Y; Jiang, R; Li, HX; Li, J; Liu, ZH; Shi, XP; Wang, F; Xiong, W | 1 |
| Fu, J; Guo, XH; Li, W; Yang, L; Yu, T; Zou, L | 1 |
| Dong, B; Pang, TT | 1 |
| Chen, DL; Liu, XX; Liu, ZH; Tang, JF; Xia, J; Zhou, MH | 1 |
| Jin, YH; Li, H; Li, Y; Lin, Y; Song, Z; Wang, YS | 1 |
| Cai, H; Ge, G; Yan, Y | 1 |
| Kim, JH; Kim, K; Kim, M; Kim, YB; Lee, S; No, JH; Suh, DH; Yun, SM | 1 |
| Chen, ZY; Kang, CM; Li, HX; Li, KF; Li, Y; Qiu, YR; Yin, XF; Zhang, Q | 1 |
| Chen, Y; Shang, H; Zhang, S; Zhang, X | 1 |
| Jiang, XH; Jin, ZH; Liu, H; Qiu, W; Wang, L | 1 |
| Gao, Q; Zheng, J | 1 |
| Cao, C; Ge, HM; Jiang, Q; Li, KR; Li, XM; Yao, J; Yao, MD; Yu, Q; Zhang, XP | 1 |
| Dai, L; Dai, Z; Dong, C; Li, J; Liu, C; Sun, Y; Yang, J; Zhang, X | 1 |
| Lv, S; Mu, Y; Xu, C; Yin, J; Zhuang, J | 1 |
| Chen, S; Fan, B; Jiang, N; Li, Y; Liu, X; Lu, C; Lv, J; Qu, L; Wang, F; Wang, Y | 1 |
| Jiang, GS; Liu, GW; Liu, YH; Ren, WD | 1 |
| Chen, L; Chen, W; Huang, W; Li, N; Lin, H; Lin, Z; Ming, Y; Xiao, J; Zheng, Y; Zheng, Z | 1 |
| Albert, M; Mingeot-Leclercq, MP; Muccioli, GG; Paquot, A; Tyteca, D; Verstraeten, SL | 1 |
| Chen, M; Fang, Z; Huang, N; Li, H; Li, Y; Luo, Y; Teng, W; Tian, J; Wu, J; Yang, X; Zhu, W | 1 |
| Chang, YS; Deng, JS; Hsieh, YH; Huang, GJ | 1 |
| Hou, J; Li, W; Wang, Z; Xue, J | 1 |
| Chen, WW; Hu, ZB; Huang, YF; Liu, DB; Liu, YM; Xiao, HX; Zhuang, YZ | 1 |
| Ren, G; Shi, Z; Teng, C; Yao, Y | 1 |
| Han, Z; Huang, H; Huang, Y; Li, W; Mai, Z; Yuan, R | 1 |
| Cao, X; Fan, M; Liu, C; Ye, Q | 1 |
| Chen, L; Gao, K; Li, P; Li, Z; Liu, J; Liu, S; Qi, Y; Qi, Z; Shao, Z; Sun, Y | 1 |
| Chen, LX; Gao, K; Li, PY; Li, SS; Li, Z; Liu, SX; Qi, YL; Qi, Z; Shao, ZJ; Sun, YS | 1 |
| Cheng, J; Li, M; Liang, J; Yu, F; Zhang, D | 1 |
| Bai, G; Guo, Y; Hou, Y; Jiang, M; Jiang, Z; Jiao, Y; Kim, U; Li, C; Ma, X; Wang, Z | 1 |
| Cui, CH; Hou, JG; Jeon, BM; Kim, SC; Yun, YJ | 1 |
| Chen, MY; Guo, YP; Huang, WH; Rao, T; Shao, L; Zhang, W; Zhou, HH | 1 |
| Li, P; Li, W; Lin, H; Liu, J; Qi, Z; Tan, J; Wang, C; Zhou, B | 1 |
| Claereboudt, EJS; Deleu, M; Janikowska-Sagan, M; Lins, L; Mingeot-Leclercq, MP; Tyteca, D; Verstraeten, SL | 1 |
| Huang, R; Li, L; Li, S; Qian, B; Qian, Y; Tian, C; Wang, B; Xiang, M; Xie, R; Yang, J; Zhang, Z | 1 |
| Chen, Y; Dong, X; Song, W; Tan, M; Zhang, Y | 2 |
| Chen, G; Du, Y; Fan, H; Meng, Q; Wang, N; Xu, H; Yang, Q; Yang, X; Zhang, J | 1 |
| Liu, FG; Zhang, WY; Zheng, YN | 1 |
| Castro-Aceituno, V; Kim, D; Kim, S; Kim, YJ; Lee, S; Liu, Y; Markus, J; Perumalsamy, H; Yang, DC | 1 |
| Ham, J; Jeong, D; Ji, HW; Kim, H; Kim, HW; Kim, SJ; Park, S | 1 |
| He, B; Li, Y; Ma, W; Ma, Y; Qin, S; Zhao, L | 1 |
| Li, X; Yang, D; Zhang, X | 1 |
| Ahn, S; Castro-Aceituno, V; Jiménez-Pérez, ZE; Jung, SK; Kim, YJ; Mathiyalagan, R; Simu, SY; Subramaniyam, S; Wang, C; Yang, DC | 1 |
| Cui, CH; Hou, J; Kim, MH; Kim, SC; Ko, E; Lee, JH; Park, S | 1 |
| Cai, N; Jin, X; Yang, Q; Zhang, Z | 1 |
| Dai, L; Hu, Y; Min, J; Qin, L; Xue, J; Zhang, J | 1 |
| Han, W; Huang, W; Ma, Y; Sun, L; Wang, B; Wang, L; Yao, D | 1 |
| Cai, Q; Liu, J; Lu, M; Sun, M; Wang, G; Wang, W; Zhang, J; Zhou, F | 1 |
| Hou, J; Jeon, B; Kim, S; Xue, J; Yun, Y | 1 |
| Liang, L; Sun, P; Wang, J; Wang, Z; Xu, M; Yuan, Y; Zhang, Y | 1 |
| Ras, R; Shahiduzzaman, M; Widmer, G | 1 |
| Jin, YH; Li, H; Li, Y; Wang, YS; Zhang, S | 1 |
| Gao, P; Kong, W; Li, Z; Liu, W; Wang, L; Wang, Z; Wu, H; Wu, J; Yu, B; Yu, X; Zhang, H | 1 |
| Long, J; Lu, C; Pan, X; Sun, M; Wu, C; Zhu, C | 1 |
| Cheng, J; Han, K; Han, M; Liang, P; Liu, S; Lu, H; Yuan, X; Zhang, Y | 1 |
| Fang, B; Fang, J; Li, Y; Wang, M; Xia, T; Xu, B; Zhang, B; Zhang, J; Zhu, X | 1 |
| Chen, N; Chu, S; Gao, Y; Hu, Y; Li, X; Lin, M; Liu, Y; Wang, H; Yang, S; Zhang, Y; Zhou, X | 1 |
| Chen, F; Chen, L; Cheng, Y; Dai, J; Li, R; Lin, Z; Zhao, Y; Zhu, Z | 1 |
| Chen, Y; Huang, H; Jiang, N; Li, Y; Liu, X; Lu, C; Lv, J; Wang, H | 1 |
| Bi, C; Feng, X; Gao, H; Li, C; Yin, J; Zhang, J | 1 |
| Alemi, A; Farrokhifar, M; Haghi Karamallah, M; Hamidieh, AA; Hosseini, SA; Soltaninejad, H; Taheri-Kafrani, A; Zare-Zardini, H | 1 |
| Bai, X; Liu, M; Liu, S; Liu, Y; Qiao, J; Wang, J; Wang, S; Zhao, D | 1 |
| Chen, L; Liu, R; Qin, Y; Wang, H; Wang, Y; Wang, Z; Zhou, M | 1 |
| Cao, R; Cheng, JY; Gao, ST; Huang, CJ; Li, B; Li, RP; Li, ZG; Liu, B; Ning, J; Zhang, BP | 1 |
| Dai, L; Guo, RT; Hu, Y; Hu, Z; Huang, JW; Min, J; Qin, L; Sun, Y | 1 |
| Ben-Eltriki, M; Deb, S; Guns, EST | 1 |
| Chen, X; He, XL; Huang, M; Lu, JJ; Shi, JJ; Wang, Y; Xu, XH | 1 |
| Chen, X; Liu, S; Lv, X; Xu, T; Zhang, J | 1 |
| Bian, S; Li, F; Liu, M; Lu, S; Wang, J; Wang, S; Yang, S; Zhang, W; Zhao, D; Zhao, Y | 1 |
| Cai, X; Han, B; Lan, X; Liu, D; Mao, X; Tu, S; Wang, H; Ye, Z; Zhang, Y; Zhang, Z; Zhou, Z; Zuo, G | 1 |
| He, C; Li, T; Shen, B; Wang, F; Zhao, W; Zhou, Y | 1 |
| Jing, L; Long, CD; Mei, QH; Qiang, FZ; Qiang, SQ; Qin, GC | 1 |
| Chen, XY; Hao, K; Liu, Y; Qian, F; Sun, Y; Wang, GJ; Wang, YY; Zha, WB; Zhang, JW; Zhou, F | 1 |
| Chen, C; Jin, YH; Li, Y; Wang, YS; Zhang, SY | 1 |
| Chai, X; Jiang, S; Liu, L; Meng, Q; Wang, H; Zhao, F | 1 |
| Liu, M; Liu, Y; Qiao, J; Wang, J; Xing, X; Yin, Y; Yu, S; Zhang, W | 1 |
| Bai, X; Bian, S; Liu, M; Lu, S; Wang, J; Wang, S; Yang, S; Zhao, D | 1 |
| Chen, F; Deng, ZY; Hu, QR; Li, J; Luo, T; Wei, WC; Wu, HC; Wu, HJ; Xu, QY; Zheng, LF | 1 |
| Chen, C; Jin, YH; Li, GA; Li, Y; Liu, WY; Wang, YS; Zhang, ET | 1 |
| Ali, MY; Chang, Q; Feng, Y; Su, Y; Wu, J; Yan, Q; Yin, L; Zhang, Y | 1 |
| Liang, Y; Zhang, J; Zhang, T; Zhao, J; Zou, H | 1 |
| Ahuja, M; Brown, A; Gazaryan, I; Hushpulian, D; Kaidery, N; Kazakov, S; Khristichenko, A; Klimovich, A; Osipyants, A; Poloznikov, A; Popov, A; Styshova, O; Thomas, B; Tishkov, V; Tsybulsky, A | 1 |
| Chen, S; Chen, X; He, Z; Lin, Z; Liu, Z; Ma, J; Wang, Y; Xie, W; Yang, S | 1 |
| Cui, C; Hou, J; Kim, S; Yun, Y | 1 |
| Feng, X; Liu, W; Wang, S; Yang, Q; Yu, B; Yu, X | 1 |
| Baek, M; Ji, HW; Jung, S; Kim, HW; Kim, SJ; Park, JE | 1 |
| Gu, JH; Guan, W; Ji, CH; Liu, Y; Shi, LS; Tang, WQ; Zhang, W | 1 |
| Ji, N; Li, M; Qi, Z; Wang, Y; Xu, F; Yan, Z; Yang, X; Zhang, A; Zhang, J | 1 |
| Garza, DL; Greimel, P; Hanashima, S; Kinoshita, M; Matsumori, N; Murata, M; Umegawa, Y | 1 |
| Cen, JK; Fu, YY; Lu, HJ; Song, HL; Song, SY; Zhang, ZJ | 1 |
| Chen, C; Han, C; Han, G; Li, H; Li, Y | 1 |
| Xiaodan, S; Ying, C | 1 |
| Hong, SH; Hwang, HJ; Moon, HS; Park, SY; Yoon, YE | 1 |
| Choi, MK; Jeon, JH; Jeon, SY; Pang, M; Park, JH; Song, IS | 1 |
| Cao, M; Cheng, Z; Jia, L; Li, Z; Shi, F; Sun, J; Wang, J; Xu, C; Yang, C; Yang, J; Zhang, W; Zhao, SC | 1 |
| Gu, H; He, X; Hu, X; Li, J; Lv, W; Pan, Y; Shi, R; Wu, A; Xu, C | 1 |
| Guan, W; Qi, W | 1 |
| Chen, F; Deng, ZY; Hong, H; Hu, QR; Huang, QX; Li, J; Luo, T; Pan, Y | 1 |
6 review(s) available for ginsenoside rh2 and ginsenosides
| Article | Year |
|---|---|
Pharmacological treatment of pure stress urinary incontinence: a narrative review.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Duloxetine Hydrochloride; Estrogen Replacement Therapy; Ginsenosides; Humans; Off-Label Use; Serotonin and Noradrenaline Reuptake Inhibitors; Urinary Incontinence, Stress | 2015 |
Anticancer property of ginsenoside Rh2 from ginseng.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Screening Assays, Antitumor; Ginsenosides; Humans; Neoplasms; Panax | 2020 |
Anticancer Effects of Ginsenoside Rh2: A Systematic Review.
Topics: Apoptosis; Cell Cycle Checkpoints; Ginsenosides; Panax | 2022 |
Advances in Biocatalytic Synthesis, Pharmacological Activities, Pharmaceutical Preparation and Metabolism of Ginsenoside Rh2.
Topics: Biocatalysis; Ginsenosides; Panax; Pharmaceutical Preparations | 2022 |
Role of ginsenoside Rh2 in tumor therapy and tumor microenvironment immunomodulation.
Topics: Ginsenosides; Immunomodulation; Neoplasms; Panax; Tumor Microenvironment | 2022 |
Ginsenoside Rh2: A shining and potential natural product in the treatment of human nonmalignant and malignant diseases in the near future.
Topics: Animals; Carcinoma, Hepatocellular; China; Ginsenosides; Humans; Liver Neoplasms; Panax | 2023 |
1 trial(s) available for ginsenoside rh2 and ginsenosides
| Article | Year |
|---|---|
Pharmacokinetics of Ginsenoside Rh2, the Major Anticancer Ingredient of Ginsenoside H Dripping Pills, in Healthy Subjects.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug; Female; Ginsenosides; Humans; Male; Young Adult | 2021 |
271 other study(ies) available for ginsenoside rh2 and ginsenosides
| Article | Year |
|---|---|
[Isolation and identification of 20(R)-ginsenoside-Rh2 (an anti-cancer constituent) from the fruits of Panax ginseng. C.A. Meyer].
Topics: Antineoplastic Agents, Phytogenic; Fruit; Ginsenosides; Panax; Plants, Medicinal; Saponins | 1991 |
Mechanism of action of ginsenoside Rh2: uptake and metabolism of ginsenoside Rh2 by cultured B16 melanoma cells.
Topics: Animals; Cell Cycle; Ginsenosides; Glycosylation; Melanoma, Experimental; Mice; Molecular Structure; Panax; Plants, Medicinal; Sapogenins; Saponins; Serum Albumin, Bovine; Triterpenes; Tumor Cells, Cultured | 1991 |
Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Cystadenocarcinoma; Dose-Response Relationship, Drug; Female; Ginsenosides; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Saponins; Tumor Cells, Cultured | 1991 |
[Induction of phenotypic reverse transformation by plant glycosides in cultured cancer cells].
Topics: Cell Differentiation; Cell Division; Cell Membrane; Cell Transformation, Neoplastic; Chemical Phenomena; Chemistry; DNA, Neoplasm; Drugs, Chinese Herbal; Genes, ras; Ginsenosides; Humans; Melanins; Melanoma, Experimental; Panax; Plants, Medicinal; Saponins; Tumor Cells, Cultured | 1989 |
[Isolation and identification of the anti-tumor constituent, ginsenoside-Rh2].
Topics: Antineoplastic Agents, Phytogenic; Chemical Phenomena; Chemistry; Ginsenosides; Panax; Plants, Medicinal; Saponins | 1988 |
[Studies on new minor saponins isolated from leaves of Panax ginseng C. A. Meyer].
Topics: Chemical Phenomena; Chemistry; Drugs, Chinese Herbal; Ginsenosides; Panax; Plants, Medicinal; Saponins | 1987 |
Involvement of peanut agglutinin-binding sugar chains in experimental metastasis of B16 melanoma cells.
Topics: Animals; Carbohydrate Sequence; Ginsenosides; Glycoproteins; Lectins; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Molecular Weight; N-Acetylneuraminic Acid; Neuraminidase; Peanut Agglutinin; Saponins; Sialic Acids | 1993 |
[Inhibitory effects of oral administration of ginsenoside Rh2 on tumor growth in nude mice bearing serous cyst adenocarcinoma of the human ovary].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Cystadenocarcinoma, Serous; Female; Ginsenosides; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Saponins | 1993 |
Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice.
Topics: Administration, Oral; Animals; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Panax; Plants, Medicinal; Saponins; Tumor Cells, Cultured | 1993 |
Ginsenoside-Rh1 and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages.
Topics: Animals; Drugs, Chinese Herbal; Enzyme Induction; Ginsenosides; Interferon-gamma; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase; Panax; Peritoneal Cavity; Plants, Medicinal; Saponins | 1996 |
G1 phase-specific suppression of the Cdk2 activity by ginsenoside Rh2 in cultured murine cells.
Topics: 3T3 Cells; Animals; CDC2-CDC28 Kinases; Cells, Cultured; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; G1 Phase; Ginsenosides; Mice; Mice, Inbred BALB C; Protein Serine-Threonine Kinases; Saponins; Tumor Cells, Cultured | 1997 |
Ginsenoside-Rh2 blocks the cell cycle of SK-HEP-1 cells at the G1/S boundary by selectively inducing the protein expression of p27kip1.
Topics: Animals; Cell Cycle Proteins; COS Cells; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; DNA, Neoplasm; Down-Regulation; G1 Phase; Ginsenosides; HeLa Cells; Humans; Liver Neoplasms; Microtubule-Associated Proteins; Rats; Saponins; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1996 |
Modulation of protein kinase C activity in NIH 3T3 cells by plant glycosides from Panax ginseng.
Topics: 3T3 Cells; Animals; Cell Division; Diglycerides; Ginsenosides; Glycosides; Mice; Panax; Plants, Medicinal; Protein Kinase C; Saponins; Type C Phospholipases | 1997 |
Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Size; Cell Survival; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Endopeptidases; Enzyme Activation; Enzyme Precursors; Flow Cytometry; Ginsenosides; Humans; Panax; Plants, Medicinal; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Saponins; Staurosporine; Transfection; Tumor Cells, Cultured | 1997 |
Properties of ginseng saponin inhibition of catecholamine secretion in bovine adrenal chromaffin cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Cardiac Glycosides; Catecholamines; Cattle; Central Nervous System Agents; Chromaffin Cells; Dose-Response Relationship, Drug; Ginsenosides; Glycyrrhizic Acid; Oleanolic Acid; Panax; Plants, Medicinal; Sapogenins; Saponins | 1998 |
Ginsenoside Rh2 and Rh3 induce differentiation of HL-60 cells into granulocytes: modulation of protein kinase C isoforms during differentiation by ginsenoside Rh2.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Differentiation; Drugs, Chinese Herbal; Ginsenosides; Granulocytes; HL-60 Cells; Humans; Isoenzymes; Panax; Phosphorylation; Plants, Medicinal; Protein Kinase C; Proteins; Saponins; Tretinoin | 1998 |
Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Saponins; Transplantation, Heterologous | 1998 |
Caspase 3 specifically cleaves p21WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells.
Topics: Amino Acid Sequence; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA Primers; Enzyme Activation; Enzyme Inhibitors; Ginsenosides; Humans; Hydrolysis; Liver Neoplasms; Molecular Sequence Data; Saponins; Sequence Homology, Amino Acid; Staurosporine; Tumor Cells, Cultured | 1998 |
[Differentiation of B16 melanoma cells induced by ginsenoside RH2].
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Cell Transformation, Neoplastic; Ginsenosides; Melanins; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Panax; Plants, Medicinal; Saponins; Tumor Cells, Cultured | 1996 |
Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carrier Proteins; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin D; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; G1 Phase; Ginsenosides; Humans; Panax; Phosphorylation; Plants, Medicinal; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Retinoblastoma-Binding Protein 1; Saponins; Transcription Factor DP1; Transcription Factors; Tumor Cells, Cultured | 1999 |
Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent pathway.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspases; DNA Fragmentation; Enzyme Activation; Ginsenosides; Glioma; Immunoblotting; Oxidative Stress; Panax; Plants, Medicinal; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species; Saponins; Tetrazolium Salts; Thiazoles; Transfection; Tumor Cells, Cultured | 1999 |
Ginsenoside Rh2 induces apoptosis independently of Bcl-2, Bcl-xL, or Bax in C6Bu-1 cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Survival; Ginsenosides; Microscopy, Electron; Panax; Plants, Medicinal; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Saponins; Time Factors; Tumor Cells, Cultured | 1999 |
Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells.
Topics: Apoptosis; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Endothelium, Vascular; Enzyme Activation; Ginsenosides; Humans; Kinetin; Microtubule-Associated Proteins; Mutation; Protein Serine-Threonine Kinases; Purines; Saponins; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2000 |
Differential expression of protein kinase C subtypes during ginsenoside Rh2-lnduced apoptosis in SK-N-BE(2) and C6Bu-1 cells.
Topics: Animals; Apoptosis; Drugs, Chinese Herbal; Ginsenosides; Humans; Isoenzymes; Protein Kinase C; Rats; Saponins; Tumor Cells, Cultured | 2000 |
Anticarcinogenic effect and enhancement of metastatic potential of BALB/c 3T3 cells by ginsenoside Rh(2).
Topics: 3T3 Cells; Animals; Anticarcinogenic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Ginsenosides; Methylcholanthrene; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Oncogene Protein pp60(v-src); Protein Serine-Threonine Kinases; Saponins; Tumor Cells, Cultured | 2001 |
Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells.
Topics: Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspase Inhibitors; Cell Division; Cysteine Proteinase Inhibitors; Drugs, Chinese Herbal; Ginsenosides; Humans; Melanoma; Oligopeptides; Panax; Skin Neoplasms; Tumor Cells, Cultured | 2002 |
[Saponins with low sugar chain from the leaves of Panax notoginseng (Burk) F. H. Chen].
Topics: Ginsenosides; Panax; Plant Leaves; Plants, Medicinal | 2002 |
SEK1-dependent JNK1 activation prolongs cell survival during G-Rh2-induced apoptosis.
Topics: Apoptosis; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Ginsenosides; Humans; Kinetics; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mutation; Tumor Cells, Cultured | 2003 |
The c-Jun N-terminal kinase 1 activity is differentially regulated by specific mechanisms during apoptosis.
Topics: Acetophenones; Amino Acid Chloromethyl Ketones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Blotting, Western; Caspase 3; Caspase Inhibitors; Caspases; Cell Death; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Proteinase Inhibitors; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Genes, Dominant; Ginsenosides; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Paclitaxel; Precipitin Tests; Protein Kinase C; Protein Kinase C-delta; Time Factors; Transfection; Up-Regulation | 2003 |
Caspase-3-mediated cleavage of Cdc6 induces nuclear localization of p49-truncated Cdc6 and apoptosis.
Topics: Active Transport, Cell Nucleus; Amino Acid Motifs; Annexin A5; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspases; CDC2-CDC28 Kinases; Cell Membrane; Cell Nucleus; Cyclin-Dependent Kinase 2; DNA Replication; Etoposide; Flow Cytometry; Ginsenosides; HeLa Cells; Humans; Membrane Glycoproteins; Nuclear Localization Signals; Paclitaxel; Phosphorylation; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Antiallergic activity of ginsenoside Rh2.
Topics: Animals; Anti-Allergic Agents; Cattle; Cell Line; Ginsenosides; Guinea Pigs; Humans; Hyaluronoglucosaminidase; Male; Mice; Mice, Inbred ICR; Panax; Passive Cutaneous Anaphylaxis; Rats | 2003 |
In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line.
Topics: alpha-Fetoproteins; Cell Cycle; Cell Differentiation; Cell Line, Tumor; gamma-Glutamyltransferase; Ginsenosides; Humans; Telomerase | 2003 |
Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants.
Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Feces; Ginsenosides; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Intestines; Panax; Saponins; Temperature; Time Factors | 2004 |
Ginsenoside Rh2 reduces ischemic brain injury in rats.
Topics: Administration, Oral; Animals; Cells, Cultured; Drugs, Chinese Herbal; Feces; Ginsenosides; Humans; Hydrochloric Acid; Intestinal Mucosa; Intestines; Male; Mice; Panax; Phytotherapy; Plant Roots; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2004 |
Ginsenosides 20(S)-protopanaxadiol and Rh2 reduce cell proliferation and increase sub-G1 cells in two cultured intestinal cell lines, Int-407 and Caco-2.
Topics: Apoptosis; Caco-2 Cells; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; G1 Phase; Ginsenosides; Humans; L-Lactate Dehydrogenase; Plant Roots; Sapogenins; Structure-Activity Relationship; Time Factors; Triterpenes; United States | 2004 |
Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Ginsenosides; Growth Inhibitors; Humans; Male; Prostatic Neoplasms | 2004 |
Mechanistic studies on protopanaxadiol, Rh2, and ginseng (Panax quinquefolius) extract induced cytotoxicity in intestinal Caco-2 cells.
Topics: Annexin A5; Apoptosis; Caco-2 Cells; Caspases; Cell Fractionation; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Ginsenosides; Humans; Isomerism; L-Lactate Dehydrogenase; Mass Spectrometry; Molecular Structure; Panax; Plant Extracts; Propidium; Sapogenins; Spectrometry, Mass, Electrospray Ionization; Time Factors; Triterpenes | 2004 |
[Induction of differentiation by ginsenoside Rh2 in hepatocarcinoma cell SMMC-7721].
Topics: Albumins; Alkaline Phosphatase; alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; gamma-Glutamyltransferase; Ginsenosides; Humans; Liver Neoplasms; Panax; Time Factors | 2004 |
[Effects of ginsenoside Rh2 on signal transduction in hepatocarcinoma SMMC-7721 cells].
Topics: Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Ginsenosides; Humans; Liver Neoplasms; Signal Transduction | 2004 |
Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ginsenosides; Humans; Mice; Mice, Inbred C57BL; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Panax; Plant Extracts; Receptors, Glucocorticoid; Tumor Suppressor Protein p53 | 2004 |
Ginsenoside Rh2 induces apoptosis via activation of caspase-1 and -3 and up-regulation of Bax in human neuroblastoma.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 1; Caspase 3; Caspases; Cell Line, Tumor; Enzyme Activation; Ginsenosides; Humans; Neuroblastoma; Panax; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2004 |
[Effect of telomerase on ginsenoside Rh2-induced differentiation of hepatocarcinoma cell line SMMC-7721].
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drugs, Chinese Herbal; Ginsenosides; Humans; Liver Neoplasms; Panax; Plants, Medicinal; RNA, Messenger; Telomerase | 2004 |
Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells.
Topics: Caco-2 Cells; Ginsenosides; Humans; Sapogenins; Triterpenes | 2005 |
Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20(R)-ginsenoside Rg3 in dog.
Topics: Administration, Oral; Animals; Blood Chemical Analysis; Chromatography, Liquid; Dogs; Female; Ginsenosides; Injections, Intra-Arterial; Male; Mass Spectrometry; Metabolic Clearance Rate; Reproducibility of Results; Sapogenins; Sensitivity and Specificity; Triterpenes | 2005 |
High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Freezing; Ginsenosides; Rats; Rats, Sprague-Dawley; Sapogenins; Spectrometry, Mass, Electrospray Ionization; Triterpenes | 2005 |
Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; G1 Phase; Ginsenosides; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Time Factors | 2005 |
[Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Panax; Random Allocation; Technetium Tc 99m Sestamibi | 2005 |
Hepatoprotective effect of 20(S)-ginsenosides Rg3 and its metabolite 20(S)-ginsenoside Rh2 on tert-butyl hydroperoxide-induced liver injury.
Topics: Animals; Cell Line, Tumor; Ginsenosides; Humans; Liver; Mice; tert-Butylhydroperoxide | 2005 |
Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; Feces; Ginsenosides; Injections, Intravenous; Male; Panax; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2005 |
Caspase-3-dependent protein kinase C delta activity is required for the progression of Ginsenoside-Rh2-induced apoptosis in SK-HEP-1 cells.
Topics: Acetophenones; Apoptosis; Benzopyrans; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Enzyme Inhibitors; Ginsenosides; Humans; Protein Kinase C-delta | 2005 |
Natural products from ginseng inhibit [3H]batrachotoxinin A 20-alpha-benzoate binding to Na+ channels in mammalian brain.
Topics: Animals; Batrachotoxins; Binding, Competitive; Cell Membrane; Cerebral Cortex; Dose-Response Relationship, Drug; Ginsenosides; Kinetics; Male; Mice; Molecular Structure; Neurons; Panax; Plant Extracts; Radioligand Assay; Sapogenins; Sodium Channels; Solubility; Synaptosomes; Triterpenes; Tritium | 2006 |
[Effects of ginsenoside Rh2(GS-Rh2) on cell cycle of Eca-109 esophageal carcinoma cell line].
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Esophageal Neoplasms; Ginsenosides; Humans; Panax; Plants, Medicinal; RNA, Messenger; Time Factors | 2005 |
Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats.
Topics: Animals; beta-Endorphin; Blood Glucose; Diabetes Mellitus, Experimental; Ginsenosides; Glucose Transporter Type 4; Male; Mice; Panax; Phytotherapy; Rats; Rats, Wistar; Receptors, Opioid, mu; Streptozocin | 2006 |
20(S)-ginsenoside Rh2, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons.
Topics: Animals; Binding Sites; Calcium; Cells, Cultured; Dose-Response Relationship, Drug; Fetus; Ginsenosides; Hippocampus; Membrane Potentials; Molecular Structure; N-Methylaspartate; Neurons; Panax; Polyamines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stereoisomerism; Structure-Activity Relationship | 2006 |
Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Topics: Animals; Antineoplastic Agents; Drug Synergism; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2006 |
Ginsenoside Rh(2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cyclophosphamide; DNA Damage; Drugs, Chinese Herbal; Female; Ginsenosides; Immunosuppressive Agents; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Micronuclei, Chromosome-Defective; Panax; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
In vitro assessment of plasma protein binding of 20(R)-ginsenoside Rh2 by equilibrium dialysis and LC-MS analysis: a case of species differences.
Topics: Animals; Blood Proteins; Chromatography, Liquid; Dialysis; Ginsenosides; Humans; Indicators and Reagents; Mass Spectrometry; Membranes, Artificial; Protein Binding; Rats; Reproducibility of Results; Species Specificity | 2006 |
Ginsenosides Rg3 and Rh2 inhibit the activation of AP-1 and protein kinase A pathway in lipopolysaccharide/interferon-gamma-stimulated BV-2 microglial cells.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Ginsenosides; Interferon-gamma; Lipopolysaccharides; Mice; Microglia; Signal Transduction; Transcription Factor AP-1 | 2006 |
[Determination of 20 (S)-ginsengnoside Rh2 in the alkali-hydrolysis product of saponins from leaves of Panax qinquefolium by RP-HPLC].
Topics: Chromatography, High Pressure Liquid; Ginsenosides; Hydrolysis; Panax; Plant Leaves; Plant Stems; Plants, Medicinal | 2006 |
Inhibitory effects of Korean red ginseng and its genuine constituents ginsenosides Rg3, Rf, and Rh2 in mouse passive cutaneous anaphylaxis reaction and contact dermatitis models.
Topics: Animals; Cytokines; Dermatitis, Contact; Female; Ginsenosides; Male; Mice; NF-kappa B; Oxazolone; Panax; Passive Cutaneous Anaphylaxis; Plant Extracts; Prostaglandin-Endoperoxide Synthases; RNA, Messenger | 2006 |
Ginsenoside-Rh2-induced mitochondrial depolarization and apoptosis are associated with reactive oxygen species- and Ca2+-mediated c-Jun NH2-terminal kinase 1 activation in HeLa cells.
Topics: Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Blotting, Western; Calcium; Caspase 3; Cell Line, Tumor; DNA Fragmentation; Flow Cytometry; Ginsenosides; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Microscopy, Confocal; Mitochondria; Mitochondrial Proteins; Reactive Oxygen Species; Signal Transduction; Subcellular Fractions; Translocation, Genetic | 2006 |
[Determination of ginsenoside Rd and its metabolites in rat urine by LC-MS].
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Ginsenosides; Injections, Intravenous; Male; Oxidation-Reduction; Panax; Plants, Medicinal; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization | 2006 |
Quantitative determination of ginsenoside Rh2 in rat biosamples by liquid chromatography electrospray ionization mass spectrometry.
Topics: Animals; Bile; Chromatography, Liquid; Feces; Female; Ginsenosides; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization | 2006 |
Ginsenoside Rh2 is one of the active principles of Panax ginseng root to improve insulin sensitivity in fructose-rich chow-fed rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet; Fructose; Ginsenosides; Injections, Intravenous; Insulin; Insulin Resistance; Male; Panax; Rats; Rats, Wistar | 2007 |
Ginsenosides compound K and Rh(2) inhibit tumor necrosis factor-alpha-induced activation of the NF-kappaB and JNK pathways in human astroglial cells.
Topics: Astrocytes; Cells, Cultured; Enzyme Activation; Enzyme Inhibitors; Fetus; Ginsenosides; Humans; Intercellular Adhesion Molecule-1; MAP Kinase Kinase 4; Models, Biological; NF-kappa B; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha | 2007 |
Determination of 25-OH-PPD in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies.
Topics: Animals; Chromatography, High Pressure Liquid; Ginsenosides; Molecular Structure; Rats; Rats, Wistar; Reproducibility of Results; Tandem Mass Spectrometry | 2007 |
Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells.
Topics: Astrocytoma; Binding Sites; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Enzymologic; Ginsenosides; Humans; Matrix Metalloproteinase 1; Matrix Metalloproteinase 14; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Molecular Structure; Neoplasm Invasiveness; NF-kappa B; Phosphorylation; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Tetradecanoylphorbol Acetate; Transcription Factor AP-1 | 2007 |
Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; AMP-Activated Protein Kinase Kinases; Animals; Anti-Obesity Agents; Cell Differentiation; Dose-Response Relationship, Drug; Ginsenosides; Mice; Protein Kinases; Signal Transduction | 2007 |
[Effect of ginsenoside Rh2 on immunocompetence of alveolar macrophages in patients with non-small cell lung cancer].
Topics: Adult; Aged; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Female; Ginsenosides; Humans; Lung Neoplasms; Macrophages, Alveolar; Male; Middle Aged; Nitric Oxide; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2007 |
Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng.
Topics: Administration, Oral; Animals; Bifidobacterium; Cholesterol; Dose-Response Relationship, Drug; Fermentation; Ginsenosides; Hypoglycemia; Hypolipidemic Agents; Male; Mice; Mice, Inbred ICR; Panax; Phytotherapy; Plant Extracts; Plant Oils; Plant Roots; Polyethylene Glycols; Polysaccharides; Saponins; Surface-Active Agents; Triglycerides; Zea mays | 2007 |
Characterizing the mechanism for ginsenoside-induced cytotoxicity in cultured leukemia (THP-1) cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Flow Cytometry; Ginsenosides; Humans; L-Lactate Dehydrogenase; Leukemia, Monocytic, Acute; Panax; Plant Extracts; Plant Leaves | 2007 |
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sapogenins; Survival Rate; Triterpenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
20(S)-protopanaxadiol and the ginsenoside Rh2 inhibit Na+ channel-activated depolarization and Na+ channel-dependent amino acid neurotransmitter release in synaptic fractions isolated from mammalian brain.
Topics: Animals; Brain; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Ginsenosides; Glutamic Acid; In Vitro Techniques; Male; Membrane Potentials; Mice; Sapogenins; Sodium Channel Blockers; Sodium Channels; Synaptosomes; Tetrodotoxin; Triterpenes; Veratridine | 2008 |
Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Astrocytes; Brain; Cell Line; Cell Proliferation; Estrogen Antagonists; Ginsenosides; Neuroprotective Agents; Pituitary Adenylate Cyclase-Activating Polypeptide; Plaque, Amyloid; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; Up-Regulation | 2008 |
Increase of adipogenesis by ginsenoside (Rh2) in 3T3-L1 cell via an activation of glucocorticoid receptor.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Cell Proliferation; Ginsenosides; Mice; Receptors, Glucocorticoid; Transcriptional Activation | 2009 |
[Effect of ginsenoside Rh2 on transplanted-tumor and expression of JAM in mice].
Topics: Animals; Cell Adhesion Molecules; Drugs, Chinese Herbal; Female; Gene Expression Regulation; Ginsenosides; Immunoglobulins; Immunohistochemistry; Male; Mice; Neoplasm Transplantation; Neoplasms; Receptors, Cell Surface | 2008 |
Improving enzymatic production of ginsenoside Rh2 from Rg3 by using nonionic surfactant.
Topics: Enzyme Stability; Fusarium; Ginsenosides; Glucosidases; Polyethylene Glycols; Surface-Active Agents | 2010 |
Anxiolytic-like effects of ginsenosides Rg3 and Rh2 from red ginseng in the elevated plus-maze model.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Buspirone; Flumazenil; Ginsenosides; Male; Maze Learning; Mice; Panax; Phytotherapy; Piperazines; Plant Extracts; Plant Roots; Pyridines; Saponins | 2009 |
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
20(R)-ginsenoside Rh2, not 20(S), is a selective osteoclastgenesis inhibitor without any cytotoxicity.
Topics: Animals; Cell Differentiation; Cell Line; Ginsenosides; Humans; Mice; Osteoclasts; Stereoisomerism | 2009 |
Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption.
Topics: Antineoplastic Agents; Apoptosis; Caveolin 1; Cholesterol; fas Receptor; Ginsenosides; HeLa Cells; Humans; Ligands; Membrane Microdomains | 2009 |
Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Biological Availability; Dogs; Drugs, Chinese Herbal; Female; Ginsenosides; Injections, Intravenous; Intestinal Absorption; Liver; Male; Protein Binding; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2009 |
Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Female; G1 Phase; Gene Knockdown Techniques; Ginsenosides; Humans; Protein Kinase Inhibitors | 2009 |
Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice.
Topics: Animals; Behavior, Animal; Bifidobacterium; Biotransformation; Disease Models, Animal; Ginsenosides; Maze Learning; Memory Disorders; Mice; Mice, Inbred ICR; Panax; Phytotherapy; Plant Extracts; Scopolamine; Swimming; Synaptic Potentials | 2009 |
[Research on the mechanism of ginsenoside Rh2 reversing the resistance of lung adenocarcinoma cells to cisplatin].
Topics: Adenocarcinoma; Apoptosis; Calcium; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Ginsenosides; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial | 2010 |
[Effect of ginsenoside Rh2 on the development of transferred tumors and chemotherapy efficiency].
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cytostatic Agents; Drug Screening Assays, Antitumor; Female; Ginsenosides; Melanoma; Mice | 2010 |
Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Ginsenosides; Humans; Male; Molecular Structure; Panax; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Structure-Activity Relationship | 2010 |
Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caveolae; Cell Line, Tumor; Cell Membrane; Cholesterol; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Ginsenosides; Humans; Male; Membrane Microdomains; Phosphorylation; Proto-Oncogene Proteins c-akt | 2010 |
Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters.
Topics: Animals; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Cell Survival; Drug Stability; Epithelial Cells; Ginsenosides; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Perfusion; Permeability; Rats; Rats, Sprague-Dawley; Stereoisomerism; Temperature; Time Factors | 2010 |
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids | 2010 |
20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Digoxin; Etoposide; Ginsenosides; Herb-Drug Interactions; Humans; Ileum; Male; Rats; Rats, Sprague-Dawley; Rhodamine 123; Terfenadine; Verapamil | 2010 |
Cholesterol-dependent induction of dendrite formation by ginsenoside Rh2 in cultured melanoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cholesterol; Dendrites; Diphenylhexatriene; Fluorescence Polarization Immunoassay; Gangliosides; Ginsenosides; Melanoma; Membrane Microdomains; Mice | 2010 |
Ginsenoside Rh2 induces Bcl-2 family proteins-mediated apoptosis in vitro and in xenografts in vivo models.
Topics: Animals; Apoptosis; Cell Line, Tumor; Down-Regulation; Female; Ginsenosides; Humans; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous | 2011 |
Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53.
Topics: Acetylcysteine; Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Free Radical Scavengers; Ginsenosides; HCT116 Cells; HEK293 Cells; Humans; Mutation; NF-kappa B; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53; Vacuoles | 2011 |
Ginsenoside Rh2 inhibits glioma cell proliferation by targeting microRNA-128.
Topics: Antineoplastic Agents; Cell Proliferation; Ginsenosides; Glioma; Humans; MicroRNAs; Molecular Targeted Therapy; Panax; Phytotherapy; Plant Extracts; Plants, Medicinal; Up-Regulation | 2011 |
Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells.
Topics: Antibiotics, Antineoplastic; Carboxy-Lyases; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Ginsenosides; Humans; Membrane Potential, Mitochondrial; Subcellular Fractions | 2012 |
Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Betulinic Acid; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Flow Cytometry; Ginsenosides; HeLa Cells; Hep G2 Cells; Humans; Molecular Structure; Neoplasms; Pentacyclic Triterpenes; Poly(ADP-ribose) Polymerases; Protein Transport; RNA Interference; Triterpenes | 2011 |
Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms.
Topics: Administration, Oral; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Caco-2 Cells; Cyclosporine; Dogs; Ginsenosides; Humans; Male; Mice; Mice, Knockout; Solubility; Stereoisomerism; Tumor Cells, Cultured; Verapamil | 2011 |
Ginsenoside Rh2(S) induces differentiation and mineralization of MC3T3-E1 cells through activation of the PKD/AMPK signaling pathways.
Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Cell Differentiation; Cell Line; Cell Proliferation; Ginsenosides; Mice; Osteoblasts; Protein Kinase C; Real-Time Polymerase Chain Reaction; Signal Transduction | 2011 |
[Effects of 20 (S) -ginsenoside Rh2 and 20 (R) -ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ginsenosides; Humans; Microscopy, Fluorescence | 2011 |
Structural modification of ginsenoside Rh(2) by fatty acid esterification and its detoxification property in antitumor.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esters; Fatty Acids; Ginsenosides; Humans; Mice; Mice, Inbred Strains; Molecular Conformation; Molecular Structure; Neoplasm Transplantation; Neoplasms, Experimental; Spleen; Structure-Activity Relationship; Thymus Gland; Xenograft Model Antitumor Assays | 2012 |
Antihyperglycemic effect of ginsenoside Rh2 by inducing islet β-cell regeneration in mice.
Topics: Animals; Cell Death; Cell Proliferation; Cyclin D; Ginsenosides; Glucose; Homeodomain Proteins; Homeostasis; Hyperplasia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Regeneration; Signal Transduction; Trans-Activators; Up-Regulation | 2012 |
A dynamic study on reversal of multidrug resistance by ginsenoside Rh₂ in adriamycin-resistant human breast cancer MCF-7 cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Ginsenosides; Humans; Microscopy, Fluorescence; Quartz Crystal Microbalance Techniques | 2012 |
Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
Topics: Animals; Base Sequence; Bone Resorption; Cell Differentiation; Cells, Cultured; DNA Primers; Down-Regulation; Genes, fos; Ginsenosides; Macrophages; MAP Kinase Signaling System; Mice; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteoporosis; Phosphorylation; Proto-Oncogene Proteins c-fos; RANK Ligand | 2012 |
Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Digoxin; Ginsenosides; Glycosylation; Humans; Inhibitory Concentration 50; Intestines; Male; Metagenome; Rats; Rats, Sprague-Dawley; Stereoisomerism | 2012 |
Sulfated derivative of 20(S)-ginsenoside Rh2 inhibits inflammatory cytokines through MAPKs and NF-kappa B pathways in LPS-induced RAW264.7 macrophages.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Ginsenosides; Inflammation; Interleukin-10; Interleukin-1beta; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Macrophages; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; RNA, Messenger; Sulfates; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2012 |
Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Ginsenosides; Humans; Liver Neoplasms; Mitochondria, Liver; Reactive Oxygen Species; Signal Transduction | 2012 |
Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
Topics: Active Transport, Cell Nucleus; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; I-kappa B Kinase; MCF-7 Cells; Mitogen-Activated Protein Kinases; NF-kappa B; Phosphorylation; Promoter Regions, Genetic; RNA Interference; Signal Transduction; Transcription Factor RelA; Transfection | 2012 |
Microbial transformation of ginsenoside Rg3 to ginsenoside Rh2 by Esteya vermicola CNU 120806.
Topics: beta-Glucosidase; Biotransformation; Ginsenosides; Hydrogen-Ion Concentration; Hydrolysis; Ophiostomatales; Temperature | 2012 |
In vitro studies on the oxidative metabolism of 20(s)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver s9.
Topics: Animals; Biotransformation; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Enzyme Inhibitors; Epoxy Compounds; Ginsenosides; Humans; Liver; Macaca fascicularis; Magnetic Resonance Spectroscopy; Male; Mice; Microsomes, Liver; Molecular Structure; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity | 2012 |
Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression.
Topics: Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Drugs, Chinese Herbal; G1 Phase; Ginsenosides; Humans; Immunoprecipitation; Leukemia; Phosphorylation; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured | 2013 |
Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chi-Square Distribution; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Statistics, Nonparametric; Up-Regulation | 2013 |
Sulfated derivatives of 20(S)-ginsenoside Rh2 and their inhibitory effects on LPS-induced inflammatory cytokines and mediators.
Topics: Animals; Cell Line; Cytokines; Gene Expression Regulation; Ginsenosides; Lipopolysaccharides; Macrophages; Mice | 2013 |
Anti-inflammatory, antioxidative and matrix metalloproteinase inhibitory properties of 20(R)-ginsenoside Rh2 in cultured macrophages and keratinocytes.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cell Line; Dinoprostone; Ginsenosides; Humans; Keratinocytes; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Nitric Oxide; Reactive Oxygen Species | 2013 |
Ginsenoside Rh2 induces human hepatoma cell apoptosisvia bax/bak triggered cytochrome C release and caspase-9/caspase-8 activation.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 8; Caspase 9; Cell Line, Tumor; Cytochromes c; Enzyme Activation; Ginsenosides; Humans; Liver Neoplasms | 2012 |
Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Ginsenosides; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Signal Transduction; Time Factors | 2013 |
Stereoselective determination of ginsenosides Rg3 and Rh2 epimers in rat plasma by LC-MS/MS: application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Ginsenosides; Male; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Tandem Mass Spectrometry | 2013 |
Inhibitory effects of sulfated 20(S)-ginsenoside Rh2 on the release of pro-inflammatory mediators in LPS-induced RAW 264.7 cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cyclooxygenase 2; Gene Expression Regulation, Enzymologic; Ginsenosides; Inflammation Mediators; Lipopolysaccharides; Macrophages; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide Synthase Type II; Phosphorylation; RNA, Messenger; Signal Transduction; Sulfates | 2013 |
Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.
Topics: Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Chromatography, Liquid; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Ginsenosides; HIV Protease Inhibitors; Humans; Injections, Intravenous; Madin Darby Canine Kidney Cells; Male; Mass Spectrometry; Rats; Rats, Wistar; Ritonavir; Tetrahydroisoquinolines; Tissue Distribution; Verapamil | 2013 |
Ginsenoside Rh2 improves learning and memory in mice.
Topics: Animals; Ginsenosides; Hippocampus; Learning; Male; Memory; Mice; Mice, Inbred ICR; Plant Extracts | 2013 |
Ginsenoside Rb1 is transformed into Rd and Rh2 by Microbacterium trichothecenolyticum.
Topics: Actinomycetales; Biotransformation; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Ginsenosides; Panax | 2013 |
Ginsenoside Rh2-B1 stimulates cell proliferation and IFN-γ production by activating the p38 MAPK and ERK-dependent signaling pathways in CTLL-2 cells.
Topics: Animals; Anti-Inflammatory Agents; CD8-Positive T-Lymphocytes; Ginsenosides; Interferon-gamma; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Virus Diseases | 2014 |
20S-Ginsenoside Rh2 induces apoptosis in human Leukaemia Reh cells through mitochondrial signaling pathways.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Ginsenosides; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Panax; Phytotherapy; Signal Transduction | 2014 |
Esterification enhanced intestinal absorption of ginsenoside Rh2 in Caco-2 cells without impacts on its protective effects against H₂O₂-induced cell injury in human umbilical vein endothelial cells (HUVECs).
Topics: Apoptosis; Caco-2 Cells; Caspase 3; Esterification; Ginsenosides; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Peroxide; Intestinal Absorption; Protective Agents | 2014 |
EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; ErbB Receptors; Ginsenosides; Glioblastoma; Humans; Male; Mice; Signal Transduction | 2014 |
p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Enzyme Activation; fas Receptor; Ginsenosides; HeLa Cells; Humans; Inhibitory Concentration 50; Mitochondria; Protein Transport; Receptors, Death Domain; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Novel multicore niosomes based on double pH-sensitive mixed micelles for Ginsenoside Rh2 delivery.
Topics: Animals; Antineoplastic Agents; Drug Liberation; Drug Stability; Ginsenosides; Hydrogen-Ion Concentration; Liposomes; MCF-7 Cells; Mice; Micelles; Polymers; Xenograft Model Antitumor Assays | 2014 |
Ginsenoside Rh2 promotes nonamyloidgenic cleavage of amyloid precursor protein via a cholesterol-dependent pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cholesterol; Disease Models, Animal; Ginsenosides; Hippocampus; Metabolic Networks and Pathways; Mice; Neurons; Peptide Fragments | 2014 |
Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFβ signaling.
Topics: Animals; Colitis; Colon; Dextran Sulfate; Ginsenosides; Male; Mice; Mice, Inbred C57BL; Signal Transduction; Transforming Growth Factor beta | 2014 |
[Ginsenoside Rh2 inhibits proliferation and promotes apoptosis of leukemia KG1-α cells].
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Flow Cytometry; Ginsenosides; Humans; Inhibitory Concentration 50; Leukemia; Time Factors; Tumor Suppressor Protein p53 | 2014 |
Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Dose-Response Relationship, Drug; Ginsenosides; Male; Molecular Structure; Plant Extracts; Rats; Rats, Sprague-Dawley | 2014 |
Treatment of stress urinary incontinence by ginsenoside Rh2.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ginsenosides; In Vitro Techniques; Mice, Inbred C57BL; Molecular Targeted Therapy; Muscle Contraction; Myosins; Nitric Oxide; Nitric Oxide Synthase Type II; Panax; Phytotherapy; Receptors, Adrenergic, alpha-1; Superoxide Dismutase; Survival of Motor Neuron 1 Protein; Swine; Urethra; Urinary Incontinence, Stress | 2014 |
Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors.
Topics: Cell Movement; Down-Regulation; Ginsenosides; Hep G2 Cells; Histone Deacetylases; Humans; Liver Neoplasms; Matrix Metalloproteinase 3; Repressor Proteins; RNA, Messenger; Tetradecanoylphorbol Acetate; Transcription Factor AP-1 | 2014 |
Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Synergism; Ginsenosides; Male; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Docking Simulation; Multidrug Resistance-Associated Proteins; Peritonitis; Protein Conformation; Pyronine; RNA, Messenger; Staphylococcal Infections; Staphylococcus aureus | 2014 |
Skin anti-photoaging properties of ginsenoside Rh2 epimers in UV-B-irradiated human keratinocyte cells.
Topics: Blotting, Western; Ginsenosides; Humans; Keratinocytes; Molecular Structure; Reactive Oxygen Species; Skin Aging; Statistics, Nonparametric; Stereoisomerism; Ultraviolet Rays | 2014 |
20(S)-Ginsenoside Rh2 as aldose reductase inhibitor from Panax ginseng.
Topics: Aldehyde Reductase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ginsenosides; Humans; Molecular Conformation; Panax; Plant Roots; Stereoisomerism; Structure-Activity Relationship | 2014 |
Synthesis and anti-cancer cell activity of pseudo-ginsenoside Rh2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ginsenosides; Humans; Molecular Structure | 2014 |
[Regulatory effect of ginsenoside Rh2 on HDAC1/2 activity and cyclin in human erythroleukemia K562 cells].
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Flow Cytometry; Ginsenosides; Histone Deacetylase 1; Histone Deacetylase 2; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Time Factors | 2014 |
Inhibition of prostatic cancer growth by ginsenoside Rh2.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Male; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Prostatic Neoplasms; Receptors, Transforming Growth Factor beta; Signal Transduction | 2015 |
Ginsenoside Rh2 inhibits growth of glioblastoma multiforme through mTor.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Ginsenosides; Glioblastoma; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Ginsenosides; Hep G2 Cells; Hepatitis B virus; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Signal Transduction; Up-Regulation | 2015 |
Study on the interaction between ginsenoside Rh2 and calf thymus DNA by spectroscopic techniques.
Topics: Animals; Cattle; Circular Dichroism; DNA; Ginsenosides; Spectrometry, Fluorescence; Thermodynamics | 2015 |
Ginsenoside Rh2 differentially mediates microRNA expression to prevent chemoresistance of breast cancer.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Female; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2015 |
Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 in HepG2 cells: disparity in cytotoxicity and autophagy-inducing effects due to 20(S)-epimers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Survival; Cells, Cultured; Ginsenosides; Hep G2 Cells; Hepatocytes; Humans; Male; Rats, Sprague-Dawley; Stereoisomerism | 2015 |
Production of bioactive ginsenosides Rh2 and Rg3 by metabolically engineered yeasts.
Topics: Ginsenosides; Glucosyltransferases; Metabolic Engineering; Panax; Plant Proteins; Saccharomyces cerevisiae | 2015 |
Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13.
Topics: Adult; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Ginsenosides; Glioblastoma; Humans; Male; Matrix Metalloproteinase 13; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Wound Healing | 2015 |
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; Ginsenosides; Humans; Neoplastic Stem Cells; Signal Transduction; Skin Neoplasms | 2015 |
Ginsenoside Rh2 Suppresses Neovascularization in Xenograft Psoriasis Model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gene Expression; Ginsenosides; Heterografts; Humans; Mice; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Psoriasis; Skin; T-Lymphocytes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2015 |
Induction of apoptosis and reversal of permeability glycoprotein-mediated multidrug resistance of MCF-7/ADM by ginsenoside Rh2.
Topics: Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; MCF-7 Cells; Real-Time Polymerase Chain Reaction | 2015 |
Ginsenoside Rh2 Mitigates Pediatric Leukemia Through Suppression of Bcl-2 in Leukemia Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Ginsenosides; Humans; Leukemia, Myeloid, Acute; Male; Mice; MicroRNAs; Neoplasm Transplantation; Proto-Oncogene Proteins c-bcl-2; Survival Analysis | 2015 |
A ROS-mediated lysosomal-mitochondrial pathway is induced by ginsenoside Rh2 in hepatoma HepG2 cells.
Topics: Apoptosis; Cathepsin B; Cell Survival; Ginsenosides; Hep G2 Cells; Humans; Lysosomes; Mitochondria; Oxidative Stress; Panax; Reactive Oxygen Species | 2015 |
Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Ginsenosides; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; K562 Cells; Leukemia; Male; MAP Kinase Signaling System; Mesenchymal Stem Cells; Mice | 2015 |
Ginsenoside Rh2 attenuates allergic airway inflammation by modulating nuclear factor-κB activation in a murine model of asthma.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Female; Ginsenosides; Immunoglobulin E; Inflammation; Interleukin-13; Interleukin-4; Interleukin-5; Lung; Mice; Mice, Inbred BALB C; NF-kappa B; Ovalbumin | 2015 |
Antidepressant-like effects of ginsenosides: A comparison of ginsenoside Rb3 and its four deglycosylated derivatives, Rg3, Rh2, compound K, and 20(S)-protopanaxadiol in mice models of despair.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Brain Chemistry; Corticosterone; Depressive Disorder; Ginsenosides; Hindlimb Suspension; Male; Mice; Motor Activity; Neurotransmitter Agents; Sapogenins; Swimming | 2016 |
Esterification of Ginsenoside Rh2 Enhanced Its Cellular Uptake and Antitumor Activity in Human HepG2 Cells.
Topics: Antineoplastic Agents; Biological Transport; Esterification; Ginsenosides; Hep G2 Cells; Humans; Molecular Structure | 2016 |
Combined Effect of Sodium Selenite and Ginsenoside Rh2 on HCT116 Human Colorectal Carcinoma Cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Culture Techniques; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Ginsenosides; HCT116 Cells; Humans; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Sodium Selenite | 2016 |
Semisynthesis and bioactive evaluation of oxidized products from 20(S)-ginsenoside Rg3, Rh2, protopanaxadiol (PPD) and their 20(R)-epimers as cytotoxic agents.
Topics: Antineoplastic Agents; Chemistry Techniques, Synthetic; Ginsenosides; HeLa Cells; Hep G2 Cells; Humans; Oxidation-Reduction; Sapogenins; Stereoisomerism; Structure-Activity Relationship; Triterpenes | 2016 |
Anti-Inflammatory Effects of Ginsenoside-Rh2 Inhibits LPS-Induced Activation of Microglia and Overproduction of Inflammatory Mediators Via Modulation of TGF-β1/Smad Pathway.
Topics: Animals; Cell Line; Cyclooxygenase 2; Ginsenosides; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Mice; Microglia; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2016 |
Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autophagy; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gene Expression; Ginsenosides; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2016 |
Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells.
Topics: Animals; Apoptosis; Azoxymethane; Carcinoma, Lewis Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dextran Sulfate; Drugs, Chinese Herbal; Energy Metabolism; Ginsenosides; Humans; Immunoblotting; Mice, Inbred C57BL; Mitochondrial Proteins; Molecular Structure; Neoplasms; Proteomics; S Phase Cell Cycle Checkpoints | 2016 |
Stereoselective pharmacokinetic and metabolism studies of 20(S)- and 20(R)-ginsenoside Rg₃ epimers in rat plasma by liquid chromatography-electrospray ionization mass spectrometry.
Topics: Animals; Chromatography, Liquid; Ginsenosides; Male; Plasma; Rats; Rats, Sprague-Dawley; Sapogenins; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Tandem Mass Spectrometry | 2016 |
Inhibition of autophagy potentiates anticancer property of 20(S)-ginsenoside Rh2 by promoting mitochondria-dependent apoptosis in human acute lymphoblastic leukaemia cells.
Topics: Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Ginsenosides; Humans; Jurkat Cells; Mitochondria; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reactive Oxygen Species; RNA Interference | 2016 |
The Octyl Ester of Ginsenoside Rh2 Induces Lysosomal Membrane Permeabilization via Bax Translocation.
Topics: Apoptosis; bcl-2-Associated X Protein; Cathepsins; Cell Proliferation; Cytosol; Esters; Gene Expression Regulation; Gene Silencing; Ginsenosides; Hep G2 Cells; Humans; Lysosomes; Membrane Potential, Mitochondrial; Membrane Proteins; Permeability; Protein Transport | 2016 |
20(S)-ginsenoside Rh2 inhibits the proliferation and induces the apoptosis of KG-1a cells through the Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drugs, Chinese Herbal; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Ginsenosides; Humans; Leukemia; Microscopy, Electron, Transmission; Panax; Real-Time Polymerase Chain Reaction; Transcription Factor 4; Transcription Factor RelA; Transcription Factors; Wnt Proteins; Wnt Signaling Pathway | 2016 |
Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Female; Ginsenosides; Isomerism; Liver Neoplasms, Experimental; Mice; Panax | 2016 |
Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-α signaling pathway.
Topics: Apoptosis; Caspases; Cell Proliferation; G1 Phase; Ginsenosides; HL-60 Cells; Humans; Leukemia; Tumor Necrosis Factor-alpha | 2016 |
Ginsenoside-Rh2 Inhibits Proliferation and Induces Apoptosis of Human Gastric Cancer SGC-7901 Side Population Cells.
Topics: Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Drugs, Chinese Herbal; Flow Cytometry; Ginsenosides; Humans; Side-Population Cells; Stomach Neoplasms; Tumor Cells, Cultured | 2016 |
The Reversal Effect and Its Mechanisms of Tetramethylpyrazine on Multidrug Resistance in Human Bladder Cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Catechin; Cell Cycle; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Neoplasm Proteins; Pyrazines; Urinary Bladder Neoplasms | 2016 |
Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Colorectal Neoplasms; Doxorubicin; Drug Synergism; Ginsenosides; Humans; Interleukin-6; Janus Kinase 2; Matrix Metalloproteinases; Signal Transduction; STAT3 Transcription Factor | 2016 |
Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin D1; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Ginsenosides; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2016 |
JNK pathway and relative transcriptional factor were involved in ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells.
Topics: A549 Cells; Activating Transcription Factor 2; Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Caspase 8; Cell Growth Processes; Cell Proliferation; G1 Phase Cell Cycle Checkpoints; Ginsenosides; Humans; Lung Neoplasms; MAP Kinase Signaling System; Transcription Factor AP-1 | 2016 |
Effect of ginsenoside Rh-2 via activation of caspase-3 and Bcl-2-insensitive pathway in ovarian cancer cells.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; Ginsenosides; Humans; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Wound Healing | 2016 |
Oral Nanomedicine Based on Multicomponent Microemulsions for Drug-Resistant Breast Cancer Treatment.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Caco-2 Cells; Coix; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Emulsions; Etoposide; Excipients; Female; Ginsenosides; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice, Inbred ICR; Mice, Nude; Nanostructures; Plant Oils; Rats, Sprague-Dawley; Seeds; Xenograft Model Antitumor Assays | 2017 |
Comparative analysis of the expression level of recombinant ginsenoside-transforming β-glucosidase in GRAS hosts and mass production of the ginsenoside Rh2-Mix.
Topics: Bacterial Proteins; beta-Glucosidase; Biotransformation; Cloning, Molecular; Corynebacterium glutamicum; Escherichia coli; Fungal Proteins; Gene Expression; Genetic Vectors; Ginsenosides; Hydrogen-Ion Concentration; Industrial Microbiology; Kinetics; Lactococcus lactis; Molecular Weight; Panax; Protein Engineering; Recombinant Proteins; Saccharomyces cerevisiae; Temperature | 2017 |
Ginsenoside Rh2 and Rg3 inhibit cell proliferation and induce apoptosis by increasing mitochondrial reactive oxygen species in human leukemia Jurkat cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Cell Survival; Gene Expression; Ginsenosides; Humans; Jurkat Cells; Matrix Metalloproteinases; Mitochondria; Reactive Oxygen Species | 2017 |
Preliminary study on fabrication, characterization and synergistic anti-lung cancer effects of self-assembled micelles of covalently conjugated celastrol-polyethylene glycol-ginsenoside Rh2.
Topics: A549 Cells; Ginsenosides; Humans; Lung Neoplasms; Micelles; Pentacyclic Triterpenes; Polyethylene Glycols; Triterpenes | 2017 |
In situ preparation of water-soluble ginsenoside Rh2-entrapped bovine serum albumin nanoparticles: in vitro cytocompatibility studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Dynamic Light Scattering; Ginsenosides; Humans; Hydrogen-Ion Concentration; Lipopolysaccharides; Magnetic Resonance Spectroscopy; Mice; Microscopy, Electron, Transmission; Nanoparticles; Serum Albumin, Bovine; Solubility; Spectroscopy, Fourier Transform Infrared; Water | 2017 |
Ginsenoside Rh2 Improves Cardiac Fibrosis via PPARδ-STAT3 Signaling in Type 1-Like Diabetic Rats.
Topics: Animals; Biomarkers; Blood Glucose; Cardiomyopathies; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Drugs, Chinese Herbal; Fibrosis; Gene Expression; Ginsenosides; Heart Function Tests; Male; Myocardium; Myocytes, Cardiac; PPAR delta; Rats; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor | 2017 |
Preparation and evaluation of self-microemulsions for improved bioavailability of ginsenoside-Rh1 and Rh2.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cytochrome P-450 Enzyme Inhibitors; Emulsions; Excipients; Ginsenosides; Humans; Lymph Nodes; Rats | 2017 |
[Ginsenoside Rh₂-induced inhibition of histone deacetylase 6 promotes K562 cells autophagy and apoptosis in vivo].
Topics: Animals; Apoptosis; Autophagy; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Ginsenosides; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylases; Humans; K562 Cells; Leukemia; Mice, Inbred BALB C; Repressor Proteins | 2016 |
[Preparation and characterization of ginsenoside-Rh₂ lipid nanoparticles and synergistic effect with borneol in resisting tumor activity].
Topics: Antineoplastic Agents; Camphanes; Cell Line, Tumor; Drug Carriers; Drug Synergism; Ginsenosides; Glioma; Humans; Lipids; Nanoparticles; Particle Size | 2016 |
LncRNA H19 contributes to Rh2-mediated MC3T3-E1cell proliferation by regulation of osteopontin.
Topics: Acetylation; Animals; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation; Ginsenosides; Histones; Mice; Osteoblasts; Osteogenesis; Osteopontin; Promoter Regions, Genetic; Protein Isoforms; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction | 2017 |
[Ginsenoside Rh₂ induces apoptosis and autophagy of K562 cells by activating p38].
Topics: Apoptosis; Autophagy; Cell Proliferation; Ginsenosides; Humans; K562 Cells; p38 Mitogen-Activated Protein Kinases | 2017 |
The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.
Topics: Annexin A2; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Ginsenosides; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B p50 Subunit | 2017 |
Ginsenoside Rh2 Inhibited Proliferation by Inducing ROS Mediated ER Stress Dependent Apoptosis in Lung Cancer Cells.
Topics: Acetylcysteine; Activating Transcription Factor 4; Apoptosis; Caspases, Initiator; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Ginsenosides; Humans; Lung Neoplasms; Phenylbutyrates; Reactive Oxygen Species; Transcription Factor CHOP; Up-Regulation | 2017 |
Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells.
Topics: Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endometrial Neoplasms; Epithelial-Mesenchymal Transition; Female; Ginsenosides; Humans; In Situ Nick-End Labeling; Signal Transduction; Transforming Growth Factor beta; Vimentin | 2017 |
Ginsenoside Rh2 inhibits human A172 glioma cell proliferation and induces cell cycle arrest status via modulating Akt signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Cyclin D; Cyclin-Dependent Kinase 4; Ginsenosides; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2018 |
Ginsenoside Rh2 inhibits proliferation and migration of medulloblastoma Daoy by down-regulation of microRNA-31.
Topics: Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Down-Regulation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Medulloblastoma; MicroRNAs; Neoplasm Proteins; RNA, Neoplasm; Wnt Signaling Pathway | 2018 |
Enhancement of oral bioavailability and immune response of Ginsenoside Rh2 by co-administration with piperine.
Topics: Administration, Oral; Alkaloids; Animals; Benzodioxoles; Biological Availability; Caco-2 Cells; Cytochrome P-450 CYP3A; Drugs, Chinese Herbal; Ginsenosides; Humans; Interleukin-2; Panax; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley | 2018 |
Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Base Sequence; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Male; MicroRNAs; Prostatic Neoplasms; Protein Biosynthesis; RNA Interference | 2018 |
Ginsenoside Rh2 inhibits vascular endothelial growth factor-induced corneal neovascularization.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anti-Inflammatory Agents; Cornea; Corneal Neovascularization; Ginsenosides; Human Umbilical Vein Endothelial Cells; Humans; Ice; Male; MAP Kinase Signaling System; Mice, Inbred ICR; Phosphoproteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
One-Pot Synthesis of Ginsenoside Rh2 and Bioactive Unnatural Ginsenoside by Coupling Promiscuous Glycosyltransferase from Bacillus subtilis 168 to Sucrose Synthase.
Topics: Arabidopsis; Arabidopsis Proteins; Bacillus subtilis; Bacterial Proteins; Ginsenosides; Glucosyltransferases; Glycosyltransferases | 2018 |
20(S)-Ginsenoside Rh2 Induce the Apoptosis and Autophagy in U937 and K562 Cells.
Topics: Apoptosis; Autophagy; Cell Proliferation; Ginsenosides; Humans; K562 Cells; Reactive Oxygen Species; U937 Cells | 2018 |
Ginsenoside Rh2 reverses sleep deprivation-induced cognitive deficit in mice.
Topics: Animals; Antioxidants; Avoidance Learning; Brain; Cognitive Dysfunction; Dose-Response Relationship, Drug; Ginsenosides; Male; Memory Disorders; Mice, Inbred ICR; Motor Activity; Nootropic Agents; Oxidative Stress; Random Allocation; Recognition, Psychology; Sleep Deprivation; Spatial Memory | 2018 |
The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Cycle; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Gene Expression; Ginsenosides; Humans; Multidrug Resistance-Associated Proteins; Phytotherapy; Tumor Cells, Cultured | 2018 |
Corilagin from longan seed: Identification, quantification, and synergistic cytotoxicity on SKOv3ip and hey cells with ginsenoside Rh2 and 5-fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Therapy, Combination; Female; Fluorouracil; Free Radical Scavengers; Ginsenosides; Glucosides; Humans; Hydrolyzable Tannins; Nitrites; Nitrosamines; Ovarian Neoplasms; Sapindaceae; Seeds | 2018 |
Membrane cholesterol delays cellular apoptosis induced by ginsenoside Rh2, a steroid saponin.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 9; Cholesterol; Ginsenosides; Humans; Membrane Fluidity; Membrane Microdomains; Mitochondria; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; THP-1 Cells; U937 Cells | 2018 |
Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Movement; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Lung Neoplasms; Macrophages; Mice; Mice, Inbred C57BL; RAW 264.7 Cells; THP-1 Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Ginsenoside Rh2 Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Regulating the TLR4/PI3K/Akt/mTOR, Raf-1/MEK/ERK, and Keap1/Nrf2/HO-1 Signaling Pathways in Mice.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Cytokines; Disease Models, Animal; Endotoxins; Extracellular Signal-Regulated MAP Kinases; Ginsenosides; Heme Oxygenase-1; Inflammation Mediators; Kelch-Like ECH-Associated Protein 1; Lung; Male; MAP Kinase Kinase Kinases; Membrane Proteins; Mice, Inbred ICR; NF-E2-Related Factor 2; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Toll-Like Receptor 4; TOR Serine-Threonine Kinases | 2018 |
Ginsenoside Rg3 and Rh2 protect trimethyltin-induced neurotoxicity via prevention on neuronal apoptosis and neuroinflammation.
Topics: Animals; Antioxidants; Apoptosis; Cell Death; Cells, Cultured; Embryo, Mammalian; Encephalitis; Ginsenosides; Neurons; Neuroprotection; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Rats; Rats, Sprague-Dawley; Trimethyltin Compounds | 2018 |
Microarray analysis of altered long non-coding RNA expression profile in liver cancer cells treated by ginsenoside Rh2.
Topics: Carcinoma, Hepatocellular; Gene Ontology; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Microarray Analysis; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; Signal Transduction | 2019 |
Antiproliferative Activity of Combined Biochanin A and Ginsenoside Rh₂ on MDA-MB-231 and MCF-7 Human Breast Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genistein; Ginsenosides; Humans; MAP Kinase Kinase Kinase 5; MCF-7 Cells; p38 Mitogen-Activated Protein Kinases; Phosphorylation; TNF Receptor-Associated Factor 2; Tumor Suppressor Protein p53 | 2018 |
Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1.
Topics: Animals; Cell Line, Tumor; Endothelial Cells; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms | 2019 |
Antimicrobial effects of the ginsenoside Rh2 on monospecies and multispecies cariogenic biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Dental Caries; Ginsenosides; Humans; Streptococcus mutans; Streptococcus sanguis; Streptococcus sobrinus | 2019 |
Immunomodulatory Effects of (24R)-Pseudo-Ginsenoside HQ and (24S)-Pseudo-Ginsenoside HQ on Cyclophosphamide-Induced Immunosuppression and Their Anti-Tumor Effects Study.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cyclophosphamide; Ginsenosides; Humans; Immunity, Innate; Immunologic Factors; Mice; Neovascularization, Pathologic; Phagocytosis; Signal Transduction; Spleen; T-Lymphocytes | 2019 |
Study on Antidepressant Activity of Pseudo-Ginsenoside HQ on Depression-Like Behavior in Mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Gene Expression Regulation; Ginsenosides; Hindlimb Suspension; Humans; Interleukin-6; Lipopolysaccharides; Mice; NF-kappa B; Signal Transduction; Swimming; Triterpenes; Tumor Necrosis Factor-alpha | 2019 |
RETRACTED: Ginsenoside Rh2 inhibits proliferation but promotes apoptosis and autophagy by down-regulating microRNA-638 in human retinoblastoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; MicroRNAs; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Retinoblastoma; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2019 |
Quantitative Proteomics Combined with Affinity MS Revealed the Molecular Mechanism of Ginsenoside Antitumor Effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Ginsenosides; Guanosine Triphosphate; Humans; Lung Neoplasms; Molecular Docking Simulation; Neoplasm Proteins; Protein Binding; Protein Conformation; Proteomics; ras Proteins; Sapogenins | 2019 |
Ginsenoside Rh2 Ameliorates Doxorubicin-Induced Senescence Bystander Effect in Breast Carcinoma Cell MDA-MB-231 and Normal Epithelial Cell MCF-10A.
Topics: Apoptosis; Breast; Breast Neoplasms; Bystander Effect; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Doxorubicin; Epithelial Cells; Female; Ginsenosides; Humans; Interleukin-6; Neoplasm Invasiveness | 2019 |
Quantification of Panax notoginseng saponins metabolites in rat plasma with in vivo gut microbiota-mediated biotransformation by HPLC-MS/MS.
Topics: Animals; Anti-Bacterial Agents; Biotransformation; Chromatography, High Pressure Liquid; Feces; Gastrointestinal Microbiome; Ginsenosides; Male; Panax notoginseng; Rats, Sprague-Dawley; Sapogenins; Saponins; Tandem Mass Spectrometry | 2019 |
Effect of ginsenoside Rh
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cisplatin; Dietary Supplements; Ginsenosides; Kidney; Male; Mass Spectrometry; Metabolome; Mice, Inbred ICR; Nephritis; Oxidative Stress; Panax | 2019 |
The activity of the saponin ginsenoside Rh2 is enhanced by the interaction with membrane sphingomyelin but depressed by cholesterol.
Topics: Animals; Cell Membrane Permeability; Chickens; Cholesterol; Egg Proteins; Ginsenosides; Membrane Fluidity; Panax; Phosphatidylcholines; Sphingomyelins; Unilamellar Liposomes | 2019 |
Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Fatty Acid Synthase, Type I; Fatty Acids; Ginsenosides; Humans; Immune Tolerance; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Sterol Regulatory Element Binding Protein 1; Xenograft Model Antitumor Assays | 2019 |
Ginsenoside Rh2 Inhibits Migration of Lung Cancer Cells under Hypoxia
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Movement; Ginsenosides; Humans; Lung Neoplasms; Matrix Metalloproteinase 9; MicroRNAs | 2019 |
In vitro and in silico evaluation of stereoselective effect of ginsenoside isomers on platelet P2Y
Topics: Animals; Blood Platelets; Fibrinolytic Agents; Ginsenosides; Glycosides; Humans; Male; Molecular Docking Simulation; Panax; Plants, Medicinal; Platelet Activation; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Sapogenins; Stereoisomerism | 2019 |
[Synthesis and anti-tumor activity of ginsenoside Rh_2 caprylic acid monoester].
Topics: Animals; Caprylates; Ginsenosides; Mice; Molecular Structure; Neoplasms, Experimental; Saponins | 2019 |
Photoluminescent And Self-Assembled Hyaluronic Acid-Zinc Oxide-Ginsenoside Rh2 Nanoparticles And Their Potential Caspase-9 Apoptotic Mechanism Towards Cancer Cell Lines.
Topics: A549 Cells; Apoptosis; Caspase 9; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Damage; Ginsenosides; Humans; Hyaluronic Acid; Luminescence; Mitochondria; Nanoparticles; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Zinc Oxide | 2019 |
Ginsenoside Rh2 Suppresses Breast Cancer Cell Proliferation by Epigenetically Regulating the Long Noncoding RNA C3orf67-AS1.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; MCF-7 Cells; Promoter Regions, Genetic; RNA, Long Noncoding | 2019 |
Oriented efficient biosynthesis of rare ginsenoside Rh2 from PPD by compiling UGT-Yjic mutant with sucrose synthase.
Topics: Amino Acid Substitution; Bacillus subtilis; Biocatalysis; Ginsenosides; Glucosyltransferases; Glycosylation; Mutant Proteins; Mutation; Sapogenins | 2020 |
Ginsenoside Rh2 induces DNA damage and autophagy in vestibular schwannoma is dependent of LAMP2 transcriptional suppression.
Topics: Apoptosis; Autophagy; Base Sequence; DNA Damage; Down-Regulation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Lysosomal Membrane Proteins; Lysosomal-Associated Membrane Protein 2; Neoplasm Proteins; Neuroma, Acoustic; NF-E2-Related Factor 2; Transcriptional Activation; Tumor Cells, Cultured | 2020 |
Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Ginsenosides; Humans; Inflammation; Lung Neoplasms; Macrophages; Mice; Polyethylene Glycols; RAW 264.7 Cells | 2019 |
Ginsenoside Rh2 Improves the Cisplatin Anti-tumor Effect in Lung Adenocarcinoma A549 Cells via Superoxide and PD-L1.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cisplatin; Drug Synergism; Drugs, Chinese Herbal; Ginsenosides; Humans; Lung Neoplasms; Superoxides | 2020 |
Ginsenoside Rh2 Ameliorates Atopic Dermatitis in NC/Nga Mice by Suppressing NF-kappaB-Mediated Thymic Stromal Lymphopoietin Expression and T Helper Type 2 Differentiation.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Line; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Models, Animal; Down-Regulation; Ginsenosides; Humans; Immunoglobulin E; Male; Mice; NF-kappa B; Skin; Th2 Cells; Thymic Stromal Lymphopoietin | 2019 |
A cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Biphenyl Compounds; Cell Proliferation; Cisplatin; Ginsenosides; Humans; Lignans; Liposomes; Lung Neoplasms; Mice; Neoplasm Invasiveness; Pentacyclic Triterpenes; Sesquiterpenes; Triterpenes; Xenograft Model Antitumor Assays | 2020 |
Biocatalytic synthesis of ginsenoside Rh2 using Arabidopsis thaliana glucosyltransferase-catalyzed coupled reactions.
Topics: Arabidopsis; Batch Cell Culture Techniques; Biocatalysis; Biosynthetic Pathways; Drugs, Chinese Herbal; Ginsenosides; Glucosyltransferases; Panax; Sapogenins; Saponins; Triterpenes; Uridine Diphosphate | 2020 |
Ginsenosides, potent inhibitors of sialyltransferase.
Topics: Gene Expression Regulation, Neoplastic; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Docking Simulation; Sialic Acids; Sialyltransferases | 2020 |
Ginsenoside Rh2 pretreatment and withdrawal reactivated the pentose phosphate pathway to ameliorate intracellular redox disturbance and promoted intratumoral penetration of adriamycin.
Topics: Doxorubicin; Ginsenosides; Oxidation-Reduction; Pentose Phosphate Pathway | 2020 |
Doxorubicin-induced normal breast epithelial cellular aging and its related breast cancer growth through mitochondrial autophagy and oxidative stress mitigated by ginsenoside Rh2.
Topics: Autophagy; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Doxorubicin; Drugs, Chinese Herbal; Female; Ginsenosides; Humans; Mitochondria; Oxidative Stress | 2020 |
20(S)-ginsenoside Rh2 as agent for the treatment of LMN-CRC via regulating epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; China; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Lymphatic Metastasis; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Signal Transduction; Vimentin | 2020 |
Effect of Ginsenoside-Rh2 and Curcurbitacin-B on Cryptosporidium parvum in vitro.
Topics: Animals; Cell Line; Coccidiostats; Cryptosporidium parvum; Cucurbitaceae; Cucurbitacins; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Ginsenosides; Inhibitory Concentration 50; Mice; Panax; Paromomycin; Plant Extracts; Real-Time Polymerase Chain Reaction; Solvents; Triterpenes | 2020 |
(20S)G-Rh2 Inhibits NF-κB Regulated Epithelial-Mesenchymal Transition by Targeting Annexin A2.
Topics: Annexin A2; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Ginsenosides; Humans; Neoplasm Invasiveness; NF-kappa B | 2020 |
Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Genetic Vectors; Ginsenosides; Humans; Leukemia, Myeloid, Acute; Mice; Oncolytic Virotherapy; Oncolytic Viruses; TNF-Related Apoptosis-Inducing Ligand; Virus Replication; Xenograft Model Antitumor Assays | 2020 |
PLGA microsphere-based composite hydrogel for dual delivery of ciprofloxacin and ginsenoside Rh2 to treat
Topics: Administration, Cutaneous; Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Delivery Systems; Drug Liberation; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Ginsenosides; HaCaT Cells; Humans; Hydrogels; Methicillin-Resistant Staphylococcus aureus; Mice; Microspheres; Polylactic Acid-Polyglycolic Acid Copolymer; Staphylococcal Skin Infections; Staphylococcus aureus | 2020 |
HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice.
Topics: Animals; Autophagy-Related Proteins; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Ginsenosides; Hep G2 Cells; Humans; Insulin; Interleukin-6; Lipolysis; Liver; Male; Metabolic Syndrome; Mice, Inbred C57BL; Mice, Knockout; Mitochondrial Proteins; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Tumor Necrosis Factor-alpha | 2020 |
New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Gastrointestinal Microbiome; Ginsenosides; Homeostasis; Humans; Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Xenograft Model Antitumor Assays | 2020 |
Structure-activity relationship analysis of dammarane-type natural products as muscle-type creatine kinase activators.
Topics: Binding Sites; Biological Products; Creatine Kinase, MM Form; Dammaranes; Ginsenosides; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Structure-Activity Relationship; Triterpenes | 2020 |
Protective effect of ginsenoside Rh2 on scopolamine-induced memory deficits through regulation of cholinergic transmission, oxidative stress and the ERK-CREB-BDNF signaling pathway.
Topics: Acetylcholinesterase; Animals; Brain-Derived Neurotrophic Factor; Cholinergic Neurons; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Ginsenosides; Hippocampus; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidative Stress; Phosphorylation; Scopolamine; Signal Transduction | 2021 |
Ginsenoside Rh2 impedes proliferation and migration and induces apoptosis by regulating NF-κB, MAPK, and PI3K/Akt/mTOR signaling pathways in osteosarcoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ginsenosides; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinases; NF-kappa B; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Cholesterol; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Fatty Acids, Monounsaturated; Ginsenosides; Hexoses; Humans; Liposomes; Male; Panax; Particle Size; PC-3 Cells; Prostatic Neoplasms; Quaternary Ammonium Compounds; Tumor Cells, Cultured | 2020 |
Ginsenoside Rh2 inhibits HeLa cell energy metabolism and induces apoptosis by upregulating voltage‑dependent anion channel 1.
Topics: Adenosine Triphosphate; Apoptosis; bcl-2-Associated X Protein; Cell Respiration; Cell Survival; Energy Metabolism; Ginsenosides; Glycolysis; HeLa Cells; Hexokinase; Humans; Membrane Potential, Mitochondrial; Models, Biological; Oxidative Phosphorylation; Reactive Oxygen Species; Stress, Physiological; Up-Regulation; Voltage-Dependent Anion Channel 1 | 2020 |
Anti-cancer Effect of 20(S)-Ginsenoside-Rh2 on Oral Squamous Cell Carcinoma Cells
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Down-Regulation; Ginsenosides; Humans; KB Cells; Matrix Metalloproteinase 2; Mouth Neoplasms; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2020 |
Structural dissection of unnatural ginsenoside-biosynthetic UDP-glycosyltransferase Bs-YjiC from Bacillus subtilis for substrate promiscuity.
Topics: Bacillus subtilis; Bacterial Proteins; Binding Sites; Crystallography, X-Ray; Ginsenosides; Glycosylation; Glycosyltransferases; Models, Molecular; Molecular Docking Simulation; Protein Domains; Sapogenins; Substrate Specificity; Uridine Diphosphate; Uridine Diphosphate Glucose | 2021 |
1α,25-Dihydroxyvitamin D
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Ginsenosides; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured; Vitamin D | 2021 |
Ginsenoside Rh2 alleviates ulcerative colitis by regulating the STAT3/miR-214 signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Disease Models, Animal; Ginsenosides; Humans; Inflammation; Male; Mice, Inbred C57BL; MicroRNAs; Signal Transduction; STAT3 Transcription Factor; Sulfasalazine | 2021 |
Knockdown of p62/sequestosome enhances ginsenoside Rh2-induced apoptosis in cervical cancer HeLa cells with no effect on autophagy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Autophagy-Related Protein 7; bcl-2-Associated X Protein; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Ginsenosides; HeLa Cells; Humans; Microtubule-Associated Proteins; NF-E2-Related Factor 2; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction | 2021 |
Integrated bioinformatic analysis and experiment confirmation of the antagonistic effect and molecular mechanism of ginsenoside Rh2 in metastatic osteosarcoma.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Computational Biology; Ginsenosides; Humans; Osteosarcoma; Phosphatidylinositol 3-Kinases | 2021 |
[Ginsenoside Rh2 inhibits renal fibrosis and renal cell apoptosis in rats with diabetic nephropathy by downregulating discoid domain receptor 1].
Topics: Animals; Apoptosis; Diabetes Mellitus; Diabetic Nephropathies; Fibrosis; Ginsenosides; Kidney; Male; Rats; Rats, Sprague-Dawley | 2021 |
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Ginsenosides; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Ginsenoside 20(S)-Rh2 promotes cellular pharmacokinetics and intracellular antibacterial activity of levofloxacin against Staphylococcus aureus through drug efflux inhibition and subcellular stabilization.
Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Stability; Female; Ginsenosides; Humans; Intracellular Fluid; Levofloxacin; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Staphylococcus aureus; Subcellular Fractions; THP-1 Cells | 2021 |
(20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.
Topics: Annexin A2; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Liver Neoplasms; STAT3 Transcription Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2021 |
Ginsenoside Rh2 stimulates the production of mitochondrial reactive oxygen species and induces apoptosis of cervical cancer cells by inhibiting mitochondrial electron transfer chain complex.
Topics: Apoptosis; Cell Survival; Female; Ginsenosides; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Molecular Docking Simulation; Oxidative Phosphorylation; Reactive Oxygen Species; Uterine Cervical Neoplasms | 2021 |
20(S)-Ginsenoside Rh2-induced apoptosis and protective autophagy in cervical cancer cells by inhibiting AMPK/mTOR pathway.
Topics: Ginsenosides | 2021 |
The immunomodulatory effects of ginsenoside derivative Rh2-O on splenic lymphocytes in H22 tumor-bearing mice is partially mediated by TLR4.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Ginsenosides; Liver Neoplasms; Lymphocytes; Mice; Spleen; Toll-Like Receptor 4 | 2021 |
(20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the HSP90A-Cdc37 System in Human Liver Cancer Cells.
Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Chaperonins; Gene Expression Regulation, Neoplastic; Ginsenosides; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; Tumor Cells, Cultured | 2021 |
Ordered Coimmobilization of Multimeric Enzyme Arrays with Enhanced Biocatalytic Cascade Performance.
Topics: Biocatalysis; Biocompatible Materials; Carbohydrate Conformation; Ginsenosides; Glycosyltransferases; Materials Testing; Models, Molecular; Particle Size | 2021 |
Identification of 20(
Topics: Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Ginsenosides; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Panax; Protein Kinase Inhibitors; Structure-Activity Relationship | 2022 |
Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2.
Topics: Adenocarcinoma; Animals; Doxorubicin; Drugs, Chinese Herbal; Ginsenosides; Mice | 2022 |
Ginsenoside Rh2 attenuates CDAHFD-induced liver fibrosis in mice by improving intestinal microbial composition and regulating LPS-mediated autophagy.
Topics: Animals; Autophagy; Ginsenosides; Hepatic Stellate Cells; Humans; Lipopolysaccharides; Liver; Liver Cirrhosis; Mice; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2022 |
Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice.
Topics: Animals; Apoptosis; Breast Neoplasms; Cardiotoxicity; Doxorubicin; Endothelial Cells; Female; Ginsenosides; Humans; Mice; Mice, Nude; Myocytes, Cardiac; Necrosis; Oxidative Stress; RNA | 2022 |
20(s)-ginsenoside Rh2 promotes TRAIL-induced apoptosis by upregulating DR5 in human hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ginsenosides; Humans; Liver Neoplasms; Mice; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2022 |
Ginsenoside Rh2 Regulates the CFAP20DC-AS1/MicroRNA-3614-3p/BBX and TNFAIP3 Axis to Induce Apoptosis in Breast Cancer Cells.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; MicroRNAs; RNA, Long Noncoding; RNA, Small Interfering; Tumor Necrosis Factor alpha-Induced Protein 3 | 2022 |
Ginsenoside Rh2 administration produces crucial antidepressant-like effects in a CUMS-induced mice model of depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Ginsenosides; Hippocampus; Mice; Stress, Psychological | 2022 |
Ginsenoside Rh2 Inhibits NLRP3 Inflammasome Activation and Improves Exosomes to Alleviate Hypoxia-Induced Myocardial Injury.
Topics: Exosomes; Ginsenosides; Humans; Hypoxia; Inflammasomes; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein | 2022 |
Behavior of Triterpenoid Saponin Ginsenoside Rh2 in Ordered and Disordered Phases in Model Membranes Consisting of Sphingomyelin, Phosphatidylcholine, and Cholesterol.
Topics: Cholesterol; Ginsenosides; Lecithins; Lipid Bilayers; Membrane Microdomains; Saponins; Sphingomyelins; Triterpenes | 2022 |
Ginsenoside Rh2 Ameliorates Neuropathic Pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Extracellular Signal-Regulated MAP Kinases; Ginsenosides; Hyperalgesia; Interleukin-6; Ligands; Mice; MicroRNAs; Neuralgia; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Toll-Like Receptor 8; Tumor Necrosis Factor-alpha | 2022 |
(20S) Ginsenoside Rh2-Activated, Distinct Apoptosis Pathways in Highly and Poorly Differentiated Human Esophageal Cancer Cells.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Ginsenosides; Humans; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2 | 2022 |
Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cell Cycle Checkpoints; Ginsenosides; Humans; Kidney Neoplasms; Sunitinib | 2022 |
Concomitant Administration of Red Ginseng Extract with Lactic Acid Bacteria Increases the Plasma Concentration of Deglycosylated Ginsenosides in Healthy Human Subjects.
Topics: Ginsenosides; Humans; Lactobacillales; Panax; Plant Extracts; Research Subjects | 2022 |
A novel autophagy activator ginsenoside Rh2 enhances the efficacy of immunogenic chemotherapy.
Topics: Autophagy; Ginsenosides | 2023 |
EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis.
Topics: Cell Line, Tumor; ErbB Receptors; Ginsenosides; Humans; Liposomes; Triple Negative Breast Neoplasms | 2023 |
Ginsenoside Rh2 and its octyl ester derivative inhibited invasion and metastasis of hepatocellular carcinoma via the c-Jun/COX2/PGE2 pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Esters; Ginsenosides; Liver Neoplasms; Mice | 2023 |